112529-15-4 | 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
250mg	99%	in stock	$8.00	$5.00
1g	99%	in stock	$10.00	$7.00
5g	99%	in stock	$25.00	$17.00
10g	99%	in stock	$32.00	$22.00
25g	99%	in stock	$49.00	$34.00

Description

• Catalog Number: AB50079
• Chemical Name: 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride
• CAS Number: 112529-15-4
• Molecular Formula: C19H21ClN2O3S
• Molecular Weight: 392.8996
• MDL Number: MFCD04975446
• SMILES: CCc1ccc(nc1)CCOc1ccc(cc1)CC1SC(=O)NC1=O.Cl

Computed Properties

• Complexity: 466
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• Undefined Atom Stereocenter Count: 1

Literature

• Molecular determinants of PPARγ partial agonism and related in silico/in vivo studies of natural saponins as potential type 2 diabetes modulators.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20180201

• Establishment of a novel mouse model for pioglitazone-induced skeletal muscle injury.

  Toxicology 20170501

• Antidiabetic effect of SN158 through PPARα/γ dual activation in ob/ob mice.

  Chemico-biological interactions 20170425

• Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.

  Oncotarget 20170321

• Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.

  Biochemical pharmacology 20160201

• Pioglitazone.

  Profiles of drug substances, excipients, and related methodology 20160101

• Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.

  Diabetes, obesity & metabolism 20150601

• Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH).

  Turkish journal of medical sciences 20150101

• Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor α, β, γ subtypes: an in silico approach.

  Journal of applied toxicology : JAT 20140701

• Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20140201

• The peroxisome proliferator-activated receptor-γ agonist pioglitazone protects against cisplatin-induced renal damage in mice.

  Journal of applied toxicology : JAT 20140101

• Antifibrotic effect of atorvastatin on paraquat-induced pulmonary fibrosis: role of PPARγ receptors.

  European journal of pharmacology 20131115

• Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model.

  Clinical and experimental pharmacology & physiology 20130901

• Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy.

  Brain : a journal of neurology 20130801

• Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20130101

• Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies.

  PloS one 20130101

• Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats.

  Neuroscience 20121213

• Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.

  Chinese medical journal 20121201

• Herb-drug pharmacokinetic interaction between radix astragali and pioglitazone in rats.

  Journal of ethnopharmacology 20121121

• Pioglitazone prevents hyperglycemia induced decrease of AdipoR1 and AdipoR2 in coronary arteries and coronary VSMCs.

  Molecular and cellular endocrinology 20121105

• [Oral antidiabetic drugs in chronic renal disease].

  Orvosi hetilap 20121104

• Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice.

  The Journal of surgical research 20121101

• A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20121101

• Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.

  Thrombosis and haemostasis 20121101

• Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products.

  Basic research in cardiology 20121101

• Vitamin E and nonalcoholic fatty liver disease.

  Current opinion in clinical nutrition and metabolic care 20121101

• Cerebral antioxidant enzyme increase associated with learning deficit in type 2 diabetes rats.

  Brain research 20121024

• Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models.

  Neuroscience letters 20121018

• Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.

  Journal of medicinal chemistry 20121011

• Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone.

  Mutation research 20121009

• Epithelial-mesenchymal transition-like phenotypic changes of retinal pigment epithelium induced by TGF-β are prevented by PPAR-γ agonists.

  Investigative ophthalmology & visual science 20121005

• Pioglitazone in acromegaly - an open-label, prospective study.

  Clinical endocrinology 20121001

• NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice.

  Psychopharmacology 20121001

• Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.

  Diabetes, obesity & metabolism 20121001

• No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.

  Diabetes, obesity & metabolism 20121001

• Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action.

  British journal of pharmacology 20121001

• Pharmacokinetics of pioglitazone in lean and obese cats.

  Journal of veterinary pharmacology and therapeutics 20121001

• Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

  Diabetes research and clinical practice 20121001

• Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1.

  Cancer prevention research (Philadelphia, Pa.) 20121001

• Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.

  The Journal of clinical endocrinology and metabolism 20121001

• Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20121001

• Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats.

  Journal of medicinal food 20121001

• Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia.

  Arteriosclerosis, thrombosis, and vascular biology 20121001

• Balancing the risks and benefits for pioglitazone in type 2 diabetes.

  Diabetes research and clinical practice 20121001

• Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

  Clinical therapeutics 20121001

• PPARγ agonists target aromatase via both PGE2 and BRCA1.

  Cancer prevention research (Philadelphia, Pa.) 20121001

• Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients.

  Chinese medical journal 20121001

• Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

  Journal of the National Cancer Institute 20120919

• Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20120904

• Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus.

  Journal of clinical pharmacology 20120901

• Mechanistic links between oxidative/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary: biochemical and pathological evidences for beneficial effect of pioglitazone.

  Human & experimental toxicology 20120901

• Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy.

  Journal of cardiovascular pharmacology and therapeutics 20120901

• Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20120901

• Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice.

  Hepatology (Baltimore, Md.) 20120901

• E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model.

  Journal of neuro-oncology 20120901

• RETRACTED: Obesity-induced increase in tumor necrosis factor-α leads to development of colon cancer in mice.

  Gastroenterology 20120901

• A study on the short-term effect of cafeteria diet and pioglitazone on insulin resistance and serum levels of adiponectin and ghrelin.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20120901

• Pioglitazone, a peroxisome proliferator activated receptor γ agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats.

  The Journal of urology 20120901

• Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.

  Bioorganic & medicinal chemistry 20120901

• Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.

  Advances in therapy 20120901

• Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.

  Advances in therapy 20120901

• Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15.

  Regulatory peptides 20120820

• Protective effect of pharmacologic preconditioning with pioglitazone on random-pattern skin flap in rat is mediated by nitric oxide system.

  The Journal of surgical research 20120801

• Pioglitazone attenuates endotoxin-induced acute lung injury by reducing neutrophil recruitment.

  The European respiratory journal 20120801

• Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation.

  Clinical science (London, England : 1979) 20120801

• Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.

  Hepatology (Baltimore, Md.) 20120801

• The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

  Diabetes, obesity & metabolism 20120801

• Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats.

  Inflammation 20120801

• Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis.

  Inflammation 20120801

• Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

  Diabetes, obesity & metabolism 20120801

• Possible involvement of PPAR-gamma receptor and nitric oxide pathway in the anticonvulsant effect of acute pioglitazone on pentylenetetrazole-induced seizures in mice.

  Epilepsy research 20120801

• Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease.

  Pharmacology, biochemistry, and behavior 20120801

• The role of ribosylated-BSA in regulating PC12 cell viability.

  Cell biology and toxicology 20120801

• Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120801

• Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.

  Journal of cardiovascular pharmacology 20120801

• PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.

  CNS neuroscience & therapeutics 20120801

• Estrogen improves vascular function via peroxisome-proliferator-activated-receptor-γ.

  Journal of molecular and cellular cardiology 20120801

• Regulation of small ubiquitin-like modifier-1, nuclear receptor coreceptor, histone deacetylase 3, and peroxisome proliferator-activated receptor-γ in human adipose tissue.

  Metabolic syndrome and related disorders 20120801

• Pioglitazone, a PPAR-γ activator, attenuates the severity of cerulein-induced acute pancreatitis by modulating early growth response-1 transcription factor.

  Translational research : the journal of laboratory and clinical medicine 20120801

• Effect of pioglitazone on transdifferentiation of preosteoblasts from rat bone mesenchymal stem cells into adipocytes.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20120801

• Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120725

• Cardioprotection from oxidative stress in the newborn heart by activation of PPARγ is mediated by catalase.

  Free radical biology & medicine 20120715

• Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes.

  Blood 20120712

• Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.

  Archives of internal medicine 20120709

• Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.

  The Journal of biological chemistry 20120706

• Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.

  The Journal of biological chemistry 20120706

• Meta-analysis confirms raised risk of bladder cancer from pioglitazone.

  BMJ (Clinical research ed.) 20120704

• The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes.

  Primary care diabetes 20120701

• A comparison of the effect of glitazones on serum sialic acid in patients with type 2 diabetes.

  Diabetes & vascular disease research 20120701

• Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells.

  Cell death and differentiation 20120701

• Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.

  Pharmacogenetics and genomics 20120701

• Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

  Diabetes care 20120701

• Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.

  Diabetologia 20120701

• Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice.

  Current cancer drug targets 20120701

• The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.

  Toxicologic pathology 20120701

• Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.

  The Journal of clinical endocrinology and metabolism 20120701

• Association between pioglitazone and urothelial bladder cancer.

  Urology 20120701

• The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes.

  Atherosclerosis 20120701

• Drug-induced hypoglycaemia in type 2 diabetes.

  Expert opinion on drug safety 20120701

• β-cell function preservation after 3.5 years of intensive diabetes therapy.

  Diabetes care 20120701

• Pioglitazone: European approval maintained despite the acknowledged risks.

  Prescrire international 20120701

• Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.

  Chinese medical journal 20120701

• Type I interferons promote fatal immunopathology by regulating inflammatory monocytes and neutrophils during Candida infections.

  PLoS pathogens 20120701

• [Clinical study of Jiangtang Xiaozhi Capsule in treating type 2 diabetes mellitus patients].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20120701

• PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells.

  Nature 20120628

• Diabetes drug is linked with bladder cancer risk.

  JAMA 20120627

• Synthesis of chalcone derivatives as potential anti-diabetic agents.

  Bioorganic & medicinal chemistry letters 20120615

• Comparable effects of pioglitazone and perindopril on circulating endothelial progenitor cells, inflammatory process and oxidative stress in patients with diabetes mellitus.

  International journal of cardiology 20120614

• NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile.

  European journal of pharmacology 20120605

• Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.

  Medical oncology (Northwood, London, England) 20120601

• Effects of pioglitazone on high-fat-diet-induced ventricular remodeling and dysfunction in rats.

  Journal of cardiovascular pharmacology and therapeutics 20120601

• Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.

  Current molecular pharmacology 20120601

• Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function.

  British journal of pharmacology 20120601

• Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study.

  Thrombosis research 20120601

• Effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with acute myocardial infarction and type 2 diabetes mellitus.

  Journal of cardiovascular pharmacology 20120601

• Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial.

  European journal of endocrinology 20120601

• Effects of peroxisome proliferator-activated receptor-γ agonists on the generation of microparticles by monocytes/macrophages.

  Cardiovascular research 20120601

• Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.

  Cardiovascular drugs and therapy 20120601

• Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.

  ChemMedChem 20120601

• Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

  Drug safety 20120601

• Recent developments and biological activities of thiazolidinone derivatives: a review.

  Bioorganic & medicinal chemistry 20120601

• Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy.

  The Journal of pharmacy and pharmacology 20120601

• Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study.

  Current medical research and opinion 20120601

• Effects of rutin on the expression of PPARγ in skeletal muscles of db/db mice.

  Planta medica 20120601

• Emodin protects against high-fat diet-induced obesity via regulation of AMP-activated protein kinase pathways in white adipose tissue.

  Planta medica 20120601

• Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance.

  Mayo Clinic proceedings 20120601

• Pioglitazone and the risk of bladder cancer.

  BMJ (Clinical research ed.) 20120530

• Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice.

  Behavioural brain research 20120516

• Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension.

  European journal of pharmacology 20120505

• Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20120501

• Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus.

  Molecular biology reports 20120501

• β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.

  The Journal of endocrinology 20120501

• Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.

  Pharmacological research 20120501

• Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20120501

• Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ.

  Brain : a journal of neurology 20120501

• A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.

  Current medical research and opinion 20120501

• High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501

• [Prospective pioglitazone clinical trial in macrovascular events].

  Nihon rinsho. Japanese journal of clinical medicine 20120501

• [Novel combined glucose-lowering drug with DPP-4 inhibitor and pioglitazone].

  Nihon rinsho. Japanese journal of clinical medicine 20120501

• Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.

  European review for medical and pharmacological sciences 20120501

• Therapeutic effects of hydrogen saturated saline on rat diabetic model and insulin resistant model via reduction of oxidative stress.

  Chinese medical journal 20120501

• Clinical efficacy of pioglitazone: generic vs. original product.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20120501

• Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide.

  Brain research bulletin 20120410

• RXR antagonism induces G0 /G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21(Cip1) pathway in adipocytes.

  The Journal of pathology 20120401

• 2-hydroxy-4'-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma.

  Journal of cardiovascular pharmacology 20120401

• Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

  Diabetologia 20120401

• Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.

  European journal of endocrinology 20120401

• Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.

  Drug safety 20120401

• PPARγ agonist pioglitazone improves scopolamine-induced memory impairment in mice.

  The Journal of pharmacy and pharmacology 20120401

• Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20120401

• Whistleblower lawsuit claims Takeda concealed harms of diabetes drug.

  BMJ (Clinical research ed.) 20120313

• Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance.

  Diabetic medicine : a journal of the British Diabetic Association 20120301

• Intermittent fasting up-regulates Fsp27/Cidec gene expression in white adipose tissue.

  Nutrition (Burbank, Los Angeles County, Calif.) 20120301

• PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.

  International journal of oncology 20120301

• Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.

  Diabetes/metabolism research and reviews 20120301

• Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.

  Drug metabolism and disposition: the biological fate of chemicals 20120301

• Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity.

  Diabetes research and clinical practice 20120301

• Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.

  American journal of physiology. Renal physiology 20120301

• Peroxisome proliferating activating receptor gamma-independent attenuation of interleukin 6 and interleukin 8 secretion from primary endometrial stromal cells by thiazolidinediones.

  Fertility and sterility 20120301

• Beneficial impact of Zingiber zerumbet on insulin sensitivity in fructose-fed rats.

  Planta medica 20120301

• Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?

  Journal of the Formosan Medical Association = Taiwan yi zhi 20120301

• Improved compressibility, flowability, dissolution and bioavailability of pioglitazone hydrochloride by emulsion solvent diffusion with additives.

  Die Pharmazie 20120301

• [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].

  Ugeskrift for laeger 20120220

• Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways.

  American journal of physiology. Cell physiology 20120215

• The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats.

  Regulatory peptides 20120210

• Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity.

  Journal of affective disorders 20120201

• PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model.

  Journal of cardiovascular electrophysiology 20120201

• Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.

  The Journal of endocrinology 20120201

• Activation of signal transducer and activator of transcription-3 by a peroxisome proliferator-activated receptor gamma agonist contributes to neuroprotection in the peri-infarct region after ischemia in oophorectomized rats.

  Stroke 20120201

• Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.

  Hypertension (Dallas, Tex. : 1979) 20120201

• Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress.

  Journal of hypertension 20120201

• Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats.

  Regulatory toxicology and pharmacology : RTP 20120201

• Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

  Diabetes care 20120201

• Pioglitazone and bladder cancer: a population-based study of Taiwanese.

  Diabetes care 20120201

• PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress.

  Molecular endocrinology (Baltimore, Md.) 20120201

• Effects of the insulin sensitizing drug, pioglitazone, and lipopolysaccharide administration on markers of systemic inflammation and clinical parameters in horses.

  Veterinary immunology and immunopathology 20120115

• Influence of a long-term high-fat diet on ghrelin secretion and ghrelin-induced food intake in rats.

  Regulatory peptides 20120110

• PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue.

  Cell metabolism 20120104

• Protective effects of PPARγ agonist in acute nephrotic syndrome.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120101

• Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.

  Research in social & administrative pharmacy : RSAP 20120101

• Pioglitazone reduces central obesity in polycystic ovary syndrome women.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20120101

• Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.

  Endocrine research 20120101

• Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial.

  Lupus 20120101

• Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.

  Diabetologia 20120101

• Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas.

  Diabetes & vascular disease research 20120101

• Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.

  Alimentary pharmacology & therapeutics 20120101

• Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20120101

• Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications.

  Laboratory animals 20120101

• Pioglitazone reduces peritoneal fibrosis via inhibition of TGF-β, MMP-2, and MMP-9 in a model of encapsulating peritoneal sclerosis.

  Renal failure 20120101

• [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20120101

• Granuloma annulare responsive to oral calcitriol.

  International journal of dermatology 20120101

• Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.

  International journal of clinical pharmacology and therapeutics 20120101

• Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.

  Current topics in medicinal chemistry 20120101

• Antioxidant and anti-inflammatory effects of a hypoglycemic fraction from Cucurbita ficifolia Bouché in streptozotocin-induced diabetes mice.

  The American journal of Chinese medicine 20120101

• Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.

  Journal of medical economics 20120101

• Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20120101

• Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.

  PloS one 20120101

• Effects of pioglitazone and/or simvastatin on circulating TNFα and adiponectin levels in insulin resistance.

  Journal of immunotoxicology 20120101

• Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells.

  Cardiovascular diabetology 20120101

• Reversible mitral and aortic regurgitation due to pioglitazone.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• Podocyte as a potential target of inflammation: role of pioglitazone hydrochloride in patients with type 2 diabetes.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.

  Acta medica Indonesiana 20120101

• Efficacy and safety of pioglitazone in type 2 diabetes mellitus: a postmarketing observational study.

  Acta medica Indonesiana 20120101

• Pioglitazone prevents capillary rarefaction in streptozotocin-diabetic rats independently of glucose control and vascular endothelial growth factor expression.

  Journal of vascular research 20120101

• Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide.

  Experimental diabetes research 20120101

• Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.

  PloS one 20120101

• The PPAR-γ agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function.

  Journal of neuroinflammation 20120101

• Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20120101

• Use of pioglitazone in patients with lichen planopilaris.

  Journal of cutaneous medicine and surgery 20120101

• Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.

  PloS one 20120101

• Pioglitazone therapy in progressive differentiated thyroid carcinoma.

  Nuklearmedizin. Nuclear medicine 20120101

• Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.

  PloS one 20120101

• Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.

  Vascular health and risk management 20120101

• The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.

  BMJ (Clinical research ed.) 20120101

• Protective effects of PPARγ agonist in glomerulosclerosis rats induced by adriamycin.

  Renal failure 20120101

• A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis.

  PloS one 20120101

• Pioglitazone--quo vadis?

  The Journal of the Association of Physicians of India 20120101

• Pioglitazone safe, so save.

  The Journal of the Association of Physicians of India 20120101

• Pioglitazone--where do we stand in India?

  The Journal of the Association of Physicians of India 20120101

• Pioglitazone and bladder cancer: the pros and cons.

  The Journal of the Association of Physicians of India 20120101

• The cage in search of a bird.

  The Journal of the Association of Physicians of India 20120101

• Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.

  Revista da Associacao Medica Brasileira (1992) 20120101

• Modification of MCF-10A cells with pioglitazone and serum-rich growth medium increases soluble factors in the conditioned medium, likely reducing BT-474 cell growth.

  International journal of molecular sciences 20120101

• [Pioglitazone, an activator of PPAR-gamma, reduces the expression of kB nuclear factor and inhibits apoptosis in mononuclear cells of peripheral blood in vitro].

  Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) 20120101

• The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.

  TheScientificWorldJournal 20120101

• Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.

  PloS one 20120101

• The adipose tissue endocrine mechanism of the prophylactic protective effect of pioglitazone in high-fat diet-induced insulin resistance.

  The Journal of international medical research 20120101

• Novel strategy to prevent atrial fibrosis and fibrillation.

  Circulation journal : official journal of the Japanese Circulation Society 20120101

• Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile.

  PloS one 20120101

• Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice.

  Asian Pacific journal of cancer prevention : APJCP 20120101

• Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.

  Journal of medicinal chemistry 20111222

• Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias.

  Circulation 20111220

• Very low density lipoprotein receptor promotes adipocyte differentiation and mediates the proadipogenic effect of peroxisome proliferator-activated receptor gamma agonists.

  Biochemical pharmacology 20111215

• Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes.

  European journal of pharmacology 20111205

• Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model.

  Brain research 20111202

• Effect of pioglitazone on cardiac sympathovagal modulation in patients with type 2 diabetes.

  Acta diabetologica 20111201

• Activation of cerebral peroxisome proliferator-activated receptors γ (PPARγ) reduces neuronal damage in the substantia nigra after transient focal cerebral ischaemia in the rat.

  Neuropathology and applied neurobiology 20111201

• Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice.

  Molecular carcinogenesis 20111201

• Metabolic effects of pioglitazone in chemically-induced mammary carcinogenesis in rats.

  Pathology oncology research : POR 20111201

• Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

  Obesity (Silver Spring, Md.) 20111201

• Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

  Diabetes, obesity & metabolism 20111201

• Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.

  Clinical and experimental nephrology 20111201

• Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts.

  Journal of vascular surgery 20111201

• Pioglitazone is a valid alternative to rosiglitazone.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20111201

• Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.

  Diabetologia 20111201

• Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture.

  The Journal of surgical research 20111201

• Imaging of a glucose analog, calcium and NADH in neurons and astrocytes: dynamic responses to depolarization and sensitivity to pioglitazone.

  Cell calcium 20111201

• Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

  Expert opinion on drug metabolism & toxicology 20111201

• Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20111201

• Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

  Clinical therapeutics 20111201

• [Estimation of individual pharmacokinetic parameters using maximum a posteriori Bayesian method with D-optimal sampling strategy].

  Yao xue xue bao = Acta pharmaceutica Sinica 20111201

• [Incretin-based therapy for treating patients with type 2 diabetes].

  Orvosi hetilap 20111127

• Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

  Diabetes, obesity & metabolism 20111101

• Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.

  Diabetes technology & therapeutics 20111101

• Cinnamaldehyde protects from the hypertension associated with diabetes.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20111101

• Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: findings from in vitro and ex vivo studies.

  Atherosclerosis 20111101

• Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.

  The Journal of clinical endocrinology and metabolism 20111101

• Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.

  Endocrinology 20111101

• Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.

  The Annals of pharmacotherapy 20111101

• Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

  Health technology assessment (Winchester, England) 20111101

• Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes.

  Diabetes/metabolism research and reviews 20111101

• Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.

  Current medical research and opinion 20111101

• Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.

  BMB reports 20111101

• [Effect of pioglitazone on hypoxia/reoxygenation injury and protein kinase C expression in neonatal rat cardiomyocytes].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20111101

• Which is the eligible patient to be treated with pioglitazone? The expert view.

  Journal of endocrinological investigation 20111101

• [Effects of pioglitazone on mitochondrial membrane potential of neonate rat's myocardial cells after hypoxia/reoxygenation].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20111101

• [Stabilization of vulnerable coronary plaque].

  Nihon rinsho. Japanese journal of clinical medicine 20111101

• [PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].

  Nihon rinsho. Japanese journal of clinical medicine 20111101

• Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway.

  Behavioural brain research 20111031

• Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.

  European journal of pharmacology 20111015

• Pioglitazone inhibits TGFβ induced keratocyte transformation to myofibroblast and extracellular matrix production.

  Molecular biology reports 20111001

• Ocular blood flow analysis detects microvascular abnormalities in impaired glucose tolerance.

  Microcirculation (New York, N.Y. : 1994) 20111001

• Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus.

  Diabetes research and clinical practice 20111001

• Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones.

  American journal of physiology. Heart and circulatory physiology 20111001

• Antiatherogenic effect of pioglitazone on uremic apolipoprotein E knockout mice by modulation of the balance of regulatory and effector T cells.

  Atherosclerosis 20111001

• High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.

  Hypertension (Dallas, Tex. : 1979) 20111001

• Peroxisome proliferator-activated receptor γ agonists accelerate oligodendrocyte maturation and influence mitochondrial functions and oscillatory Ca(2+) waves.

  Journal of neuropathology and experimental neurology 20111001

• Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20111001

• Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging.

  JACC. Cardiovascular imaging 20111001

• Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.

  JACC. Cardiovascular imaging 20111001

• Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.

  JACC. Cardiovascular imaging 20111001

• Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?

  JACC. Cardiovascular imaging 20111001

• [A randomized, double blind, placebo-controlled, parallel and multicenter study to evaluate the safety and efficacy of pioglitazone with sulphonylurea in type 2 diabetic patients].

  Zhonghua nei ke za zhi 20111001

• Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats.

  Neuroscience 20110929

• Evaluation of PPARγ agonists on rodent endothelial cell proliferation.

  Toxicology 20110905

• Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.

  Neurobiology of aging 20110901

• Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).

  Diabetes, obesity & metabolism 20110901

• A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.

  Diabetes, obesity & metabolism 20110901

• Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus.

  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20110901

• Assessing the influences on therapeutic intensification in type 2 diabetes mellitus according to career stage.

  Diabetes research and clinical practice 20110901

• Effects of pioglitazone on renal calcium excretion.

  The Journal of clinical endocrinology and metabolism 20110901

• Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.

  Clinical therapeutics 20110901

• Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.

  International journal of clinical practice 20110901

• [The protection of islet β-cells in db/db mice by combination pioglitazone and glucagon like peptide-1 treatment].

  Zhonghua nei ke za zhi 20110901

• [Pioglitazone].

  Nihon rinsho. Japanese journal of clinical medicine 20110901

• Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, induces dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels.

  Investigative ophthalmology & visual science 20110824

• Effect of pioglitazone on altered expression of Aβ metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance.

  European journal of pharmacology 20110816

• Lowering the triglyceride/high-density lipoprotein cholesterol and its association with the beneficial impact of pioglitazone on coronary atherosclerosis in the PERISCOPE study is likely due to lowering insulin resistance.

  Journal of the American College of Cardiology 20110809

• Macrovascular effects and safety issues of therapies for type 2 diabetes.

  The American journal of cardiology 20110802

• Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study.

  Biomedical chromatography : BMC 20110801

• The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss.

  Obesity (Silver Spring, Md.) 20110801

• High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive.

  Diabetes, obesity & metabolism 20110801

• Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats.

  European journal of pharmacology 20110801

• PPARγ dependence of cyclosporine-isoprenaline renovascular interaction: roles of nitric oxide synthase and heme oxygenase.

  Journal of cardiovascular pharmacology 20110801

• Optimal study design for pioglitazone in septic pediatric patients.

  Journal of pharmacokinetics and pharmacodynamics 20110801

• Pioglitazone promotes preadipocyte proliferation by downregulating p16(Ink4a).

  Biochemical and biophysical research communications 20110729

• Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.

  European journal of pharmacology 20110715

• Effect of pioglitazone on endothelial dysfunction after sirolimus-eluting stent implantation.

  The American journal of cardiology 20110715

• Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.

  Brain research bulletin 20110715

• Pioglitazone for diabetes prevention.

  The New England journal of medicine 20110714

• Pioglitazone for diabetes prevention.

  The New England journal of medicine 20110714

• Diabetes drug may be associated with increase in risk of bladder cancer.

  JAMA 20110713

• Peroxisome proliferator-activated receptor-γ agonists prevent in vivo remodeling of human artery induced by alloreactive T cells.

  Circulation 20110712

• Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.

  Circulation 20110705

• Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.

  Metabolism: clinical and experimental 20110701

• Adipose triglyceride lipase expression in human adipose tissue and muscle. Role in insulin resistance and response to training and pioglitazone.

  Metabolism: clinical and experimental 20110701

• Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.

  Diabetes, obesity & metabolism 20110701

• Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization.

  Drug delivery 20110701

• Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

  Diabetes, obesity & metabolism 20110701

• Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures.

  Diabetes/metabolism research and reviews 20110701

• Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.

  Diabetes research and clinical practice 20110701

• Effect of pioglitazone on diabetic nephropathy and expression of HIF-1α and VEGF in the renal tissues of type 2 diabetic rats.

  Diabetes research and clinical practice 20110701

• Low HDL-cholesterol: a strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes.

  Diabetes research and clinical practice 20110701

• Review of approved pioglitazone combinations for type 2 diabetes.

  Expert opinion on pharmacotherapy 20110701

• Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus.

  Expert opinion on pharmacotherapy 20110701

• Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.

  Journal of diabetes science and technology 20110701

• European drug agency extends review of safety of pioglitazone.

  BMJ (Clinical research ed.) 20110629

• Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes.

  Life sciences 20110606

• Low-serum culture system improves the adipogenic ability of visceral adipose tissue-derived stromal cells.

  Cell biology international 20110601

• Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20110601

• Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors.

  Experimental neurology 20110601

• Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists.

  Brain, behavior, and immunity 20110601

• DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.

  Diabetic medicine : a journal of the British Diabetic Association 20110601

• PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.

  Diabetes technology & therapeutics 20110601

• Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20110601

• Pioglitazone attenuates acute cocaine toxicity in rat isolated heart: potential protection by metabolic modulation.

  Anesthesiology 20110601

• Pharmacokinetics of pioglitazone after multiple oral dose administration in horses.

  Journal of veterinary pharmacology and therapeutics 20110601

• Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms.

  Journal of neurotrauma 20110601

• Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.

  Diabetes care 20110601

• Novel ligands that target the mitochondrial membrane protein mitoNEET.

  Journal of molecular graphics & modelling 20110601

• Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20110601

• Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease.

  Brain research bulletin 20110530

• Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.

  The Journal of biological chemistry 20110527

• Pioglitazone suppresses advanced glycation end product-induced expression of plasminogen activator inhibitor-1 in vascular smooth muscle cells.

  Journal of genetics and genomics = Yi chuan xue bao 20110520

• Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.

  Nature reviews. Endocrinology 20110510

• Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.

  Mucosal immunology 20110501

• Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.

  Diabetes, obesity & metabolism 20110501

• Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.

  Diabetes/metabolism research and reviews 20110501

• Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.

  Diabetes/metabolism research and reviews 20110501

• Peroxisome proliferator-activated receptor-γ stimulates 11β-hydroxysteroid dehydrogenase type 1 in rat vascular smooth muscle cells.

  Steroids 20110501

• Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner.

  Basic research in cardiology 20110501

• The safety of thiazolidinediones.

  Expert opinion on drug safety 20110501

• Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis.

  Atherosclerosis 20110501

• Is telomerase a potential target for vascular rejuvenation?

  Atherosclerosis 20110501

• Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.

  International journal of clinical practice 20110501

• [Glycemic control and cardiovascular benefit: what do we know today?].

  Deutsche medizinische Wochenschrift (1946) 20110501

• [A compounding agent of alogliptin and pioglitazone].

  Nihon rinsho. Japanese journal of clinical medicine 20110501

• Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.

  Canadian journal of physiology and pharmacology 20110501

• Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.

  Journal of diabetes science and technology 20110501

• Rosiglitazone saga. Demonisation of rosiglitazone.

  BMJ (Clinical research ed.) 20110421

• Pioglitazone: a promising therapeutic tool in sodium taurocholate-induced severe acute pancreatitis.

  Digestive diseases and sciences 20110401

• Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.

  Arteriosclerosis, thrombosis, and vascular biology 20110401

• Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking.

  Biological psychiatry 20110401

• Assessment of the environmental fate and effects of the PPARgamma receptor agonist, pioglitazone.

  Chemosphere 20110401

• Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20110401

• Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?

  Nature reviews. Endocrinology 20110401

• Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

  Diabetes care 20110401

• Cohort study of pioglitazone and cancer incidence in patients with diabetes.

  Diabetes care 20110401

• Insulin sensitizers in nonalcoholic steatohepatitis.

  Hepatology (Baltimore, Md.) 20110401

• Targets of the peroxisome proliferator-activated receptor γ agonist trials for the prevention of Alzheimer disease.

  Archives of neurology 20110401

• Peroxisome proliferator-activated receptor-gamma agonist induces regulatory T cells in a murine model of allergic rhinitis.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20110401

• Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.

  Diabetes & vascular disease research 20110401

• Pioglitazone for diabetes prevention in impaired glucose tolerance.

  The New England journal of medicine 20110324

• Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis.

  Fertility and sterility 20110315

• Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats.

  Toxicology and applied pharmacology 20110315

• Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway.

  Neuroscience 20110310

• Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.

  Clinical endocrinology 20110301

• Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits β-catenin-mediated glioma cell growth and invasion.

  Molecular and cellular biochemistry 20110301

• Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects.

  Atherosclerosis 20110301

• Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone.

  Diabetes care 20110301

• Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis.

  JACC. Cardiovascular interventions 20110301

• The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.

  Journal of diabetes science and technology 20110301

• [Clinical vignette. Which combination of oral glucose-lowering agents to use after failure of metformin monotherapy in type 2 diabetes?].

  Revue medicale de Liege 20110301

• Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.

  Acta gastro-enterologica Belgica 20110301

• Switching from rosiglitazone: thinking outside the class.

  JAMA 20110223

• Differential effects of PPARgamma ligands on oxidative stress-induced death of retinal pigmented epithelial cells.

  Investigative ophthalmology & visual science 20110222

• Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function.

  Biochemical pharmacology 20110215

• Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.

  Metabolism: clinical and experimental 20110201

• Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.

  Metabolism: clinical and experimental 20110201

• Controlling cardiomyocyte length: the role of renin and PPAR-{gamma}.

  Cardiovascular research 20110201

• Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.

  Heart rhythm 20110201

• Inflammatory responses in the atria: should they stay or should they go?

  Heart rhythm 20110201

• Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ mediates pioglitazone-reduced vascular lesion formation.

  Arteriosclerosis, thrombosis, and vascular biology 20110201

• Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production.

  Journal of molecular endocrinology 20110201

• Insulin resistance secondary to a high-fat diet stimulates longitudinal bone growth and growth plate chondrogenesis in mice.

  Endocrinology 20110201

• Peroxisome proliferator-activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo.

  Glia 20110201

• Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA).

  Current medical research and opinion 20110201

• PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.

  American journal of physiology. Renal physiology 20110201

• Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.

  Endocrinology 20110201

• Simultaneous determination of gliquidone, pioglitazone hydrochloride, and verapamil in formulation and human serum by RP-HPLC.

  Journal of chromatographic science 20110201

• Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

  International journal of clinical practice 20110201

• Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.

  Diabetes care 20110201

• [Anti-atherosclerotic effect of pioglitazone--the first evidence of the role of triglyceride/HDL ratio].

  Lege artis medicinae : uj magyar orvosi hirmondo 20110201

• Pretreatment of human mesenchymal stem cells with pioglitazone improved efficiency of cardiomyogenic transdifferentiation and cardiac function.

  Stem cells (Dayton, Ohio) 20110201

• Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?

  Annals of internal medicine 20110118

• Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

  Annals of internal medicine 20110118

• Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

  The New England journal of medicine 20110113

• Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.

  Journal of the American College of Cardiology 20110111

• Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice.

  European journal of pharmacology 20110110

• Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.

  Biochemical and biophysical research communications 20110107

• Pioglitazone modulates the balance of effector and regulatory T cells in apolipoprotein E deficient mice.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20110101

• Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids.

  Cancer chemotherapy and pharmacology 20110101

• Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20110101

• Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.

  Fertility and sterility 20110101

• Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease.

  Behavioural brain research 20110101

• Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus.

  Journal of diabetes and its complications 20110101

• A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease.

  Archives of neurology 20110101

• Interaction study of pioglitazone with albumin by fluorescence spectroscopy and molecular docking.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20110101

• Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.

  American journal of physiology. Endocrinology and metabolism 20110101

• Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.

  European journal of endocrinology 20110101

• Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury.

  Experimental neurology 20110101

• Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis.

  Kidney & blood pressure research 20110101

• Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.

  Diabetes, obesity & metabolism 20110101

• Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.

  Current medical research and opinion 20110101

• Pioglitazone-induced progressive pancytopenia.

  The Annals of pharmacotherapy 20110101

• [Prevention, treatment and management of inflammation in atherosclerosis].

  Nihon rinsho. Japanese journal of clinical medicine 20110101

• [Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes].

  Nihon rinsho. Japanese journal of clinical medicine 20110101

• Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.

  PloS one 20110101

• Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.

  Postgraduate medicine 20110101

• Effects of the insulin-sensitizing drug pioglitazone and lipopolysaccharide administration on insulin sensitivity in horses.

  Journal of veterinary internal medicine 20110101

• Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

  Cardiovascular diabetology 20110101

• A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations.

  Acta medica Indonesiana 20110101

• The ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice.

  PloS one 20110101

• Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies.

  Arzneimittel-Forschung 20110101

• Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions.

  Arzneimittel-Forschung 20110101

• Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents.

  Circulation journal : official journal of the Japanese Circulation Society 20110101

• The effects of an arabinogalactan-protein from the white-skinned sweet potato (Ipomoea batatas L.) on blood glucose in spontaneous diabetic mice.

  Bioscience, biotechnology, and biochemistry 20110101

• Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

  BMJ (Clinical research ed.) 20110101

• Oral pioglitazone reduces infarction volume and improves neurologic function following MCAO in rats.

  Advances in experimental medicine and biology 20110101

• Tumor necrosis factor-α and interleukin-6 expression in leukocytes and their association with polymorphisms and bone markers in diabetic individuals treated with pioglitazone.

  Drug metabolism and drug interactions 20110101

• Three-year clinical outcome in type 2 diabetic patients with drug-eluting stents versus bare-metal stents with pioglitazone.

  Cardiovascular revascularization medicine : including molecular interventions 20110101

• Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.

  Endocrine journal 20110101

• Determinants of an optimal response to pioglitazone in terms of HDL-cholesterol.

  Internal medicine (Tokyo, Japan) 20110101

• [Correction of negative influence of long-term hypergastrinemia on gastric acid secretion].

  Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) 20110101

• Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats.

  Biological & pharmaceutical bulletin 20110101

• Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats.

  Biological & pharmaceutical bulletin 20110101

• Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.

  BMC clinical pharmacology 20110101

• Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction.

  Circulation journal : official journal of the Japanese Circulation Society 20110101

• Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.

  Journal of pharmacological sciences 20110101

• Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.

  Cardiovascular diabetology 20110101

• [Evidences demonstrating the effects of prevention of major adverse cardiovascular events and anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive study and PERISCOPE study].

  Nihon rinsho. Japanese journal of clinical medicine 20110101

• The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.

  Journal of neuroinflammation 20110101

• Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension.

  Pharmacology 20110101

• [Clinical description of effectiveness of pioglitazone in a complex therapy of patients with ischemic heart disease on background of metabolic syndrome].

  Likars'ka sprava 20110101

• Role of activation of 5'-adenosine monophosphate-activated protein kinase in gastric ulcer healing in diabetic rats.

  Pharmacology 20110101

• Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.

  PloS one 20110101

• Development and validation of new assay method for the simultaneous analysis of diltiazem, metformin, pioglitazone and rosiglitazone by RP-HPLC and its applications in pharmaceuticals and human serum.

  Journal of chromatographic science 20110101

• Investigation of the antibacterial activity of pioglitazone.

  Drug design, development and therapy 20110101

• Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.

  PloS one 20110101

• Mining relational paths in integrated biomedical data.

  PloS one 20110101

• Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.

  PloS one 20110101

• Acute mitochondrial actions of glitazones on the liver: a crucial parameter for their antidiabetic properties.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20110101

• Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.

  PloS one 20110101

• [The effectiveness of pioglitazone in the treatment of patients with coronary heart disease on the background of metabolic syndrome].

  Likars'ka sprava 20110101

• Advanced glycation end products downregulates peroxisome proliferator-activated receptor γ expression in cultured rabbit chondrocyte through MAPK pathway.

  European journal of pharmacology 20101215

• Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with α-glucosidase inhibitor.

  Autonomic neuroscience : basic & clinical 20101208

• The relationship between GPR40 and lipotoxicity of the pancreatic β-cells as well as the effect of pioglitazone.

  Biochemical and biophysical research communications 20101203

• Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes.

  Acta diabetologica 20101201

• Roles of peroxisome proliferator-activated receptor-alpha and -gamma in the development of non-small cell lung cancer.

  American journal of respiratory cell and molecular biology 20101201

• Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20101201

• Modular therapy approach in metastatic castration-refractory prostate cancer.

  World journal of urology 20101201

• Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20101201

• Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system.

  Neuropathology and applied neurobiology 20101201

• Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.

  Current opinion in obstetrics & gynecology 20101201

• Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.

  British journal of pharmacology 20101201

• Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.

  Current opinion in lipidology 20101201

• Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

  Current osteoporosis reports 20101201

• CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.

  The Journal of clinical endocrinology and metabolism 20101201

• Increased frequency of micronuclei in diabetes mellitus patients using pioglitazone and glimepiride in combination.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20101201

• Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.

  Clinical endocrinology 20101201

• The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis.

  Diabetes research and clinical practice 20101201

• Pioglitazone has direct effects on insulin sensitivity and intracellular lipid content in L6 skeletal muscle cells.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20101201

• Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.

  Arteriosclerosis, thrombosis, and vascular biology 20101201

• Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application.

  Biomedical chromatography : BMC 20101201

• Solubility of pioglitazone hydrochloride in binary and ternary mixtures of water, propylene glycol, and polyethylene glycols 200, 400, and 600 at 298.2 k.

  AAPS PharmSciTech 20101201

• Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes.

  Journal of clinical hypertension (Greenwich, Conn.) 20101201

• Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study.

  Journal of evaluation in clinical practice 20101201

• Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone.

  Chinese medical journal 20101201

• Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.

  Journal of atherosclerosis and thrombosis 20101127

• PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease.

  Blood 20101125

• Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome.

  BJU international 20101101

• Inverse association of PPARγ agonists use and high grade glioma development.

  Journal of neuro-oncology 20101101

• PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20101101

• RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells.

  Cancer letters 20101101

• Multidrug therapy in a patient with Rabson-Mendenhall syndrome.

  Diabetologia 20101101

• Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.

  Diabetes care 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice.

  Molecular cancer therapeutics 20101101

• Efficacy and safety of generic and original pioglitazone in type 2 diabetes mellitus: a multicenter, a double-blinded, randomized-controlled study.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20101101

• [Thiazolidinediones].

  Nihon rinsho. Japanese journal of clinical medicine 20101101

• [Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].

  Rinsho shinkeigaku = Clinical neurology 20101101

• Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.

  Neuroscience 20101027

• Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.

  Drugs 20101022

• Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}.

  Circulation research 20101015

• SLCO1B1 polymorphism and oral antidiabetic drugs.

  Basic & clinical pharmacology & toxicology 20101001

• Meal fat storage in subcutaneous adipose tissue: comparison of pioglitazone and glipizide treatment of type 2 diabetes.

  Obesity (Silver Spring, Md.) 20101001

• Generation, validation and humanisation of a novel insulin resistant cell model.

  Biochemical pharmacology 20101001

• Potential role of pioglitazone, caffeic acid and their combination against fatigue syndrome-induced behavioural, biochemical and mitochondrial alterations in mice.

  Inflammopharmacology 20101001

• Thiazolidinediones and fractures: evidence from translating research into action for diabetes.

  The Journal of clinical endocrinology and metabolism 20101001

• Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging.

  Arteriosclerosis, thrombosis, and vascular biology 20101001

• Improvement of psoriatic arthritis by pioglitazone treatment in a type 2 diabetic patient.

  Diabetes research and clinical practice 20101001

• The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis.

  European journal of internal medicine 20101001

• Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.

  Journal of clinical pharmacy and therapeutics 20101001

• Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy.

  Diabetic medicine : a journal of the British Diabetic Association 20101001

• Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein.

  British journal of pharmacology 20101001

• Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.

  International journal of clinical pharmacology and therapeutics 20101001

• Evaluation of anti-inflammatory and chondroprotective effects of peroxisome proliferator-activated receptor gamma agonists in cartilage and synovial explants from dogs.

  American journal of veterinary research 20101001

• Meta-analysis and moderation.

  Nature reviews. Drug discovery 20101001

• Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice.

  Life sciences 20100925

• Anticonvulsant potential of the peroxisome proliferator-activated receptor γ agonist pioglitazone in pentylenetetrazole-induced acute seizures and kindling in mice.

  Brain research 20100910

• Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study.

  Clinical endocrinology 20100901

• Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetes.

  Atherosclerosis 20100901

• Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.

  Arteriosclerosis, thrombosis, and vascular biology 20100901

• Pioglitazone in chemically induced mammary carcinogenesis in rats.

  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20100901

• Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats.

  European journal of pharmacology 20100901

• Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20100901

• Pioglitazone in the treatment of NASH: the role of adiponectin.

  Alimentary pharmacology & therapeutics 20100901

• Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population.

  Circulation. Cardiovascular quality and outcomes 20100901

• Solubility of pioglitazone hydrochloride in binary mixtures of polyethylene glycol 400 with ethanol, propylene glycol, N-methyl-2-pyrrolidone, and water at 25 degrees C.

  Chemical & pharmaceutical bulletin 20100901

• Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).

  Journal of diabetes 20100901

• Revisiting the rosiglitazone story--lessons learned.

  The New England journal of medicine 20100826

• [Effect of pioglitazone on receptor activator of nuclear factor-kappa B expression in osteoclast from RAW264.7 cells].

  Zhonghua yi xue za zhi 20100824

• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  Lancet (London, England) 20100807

• Individualised incretin-based treatment for type 2 diabetes.

  Lancet (London, England) 20100807

• Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis.

  Neuropathology : official journal of the Japanese Society of Neuropathology 20100801

• Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20100801

• Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury.

  Cardiovascular research 20100801

• Pioglitazone preserves vein graft integrity in a rat aortic interposition model.

  The Journal of thoracic and cardiovascular surgery 20100801

• Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation.

  British journal of pharmacology 20100801

• Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells.

  Journal of lipid research 20100801

• Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals.

  Diabetologia 20100801

• Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease.

  Pharmacology, biochemistry, and behavior 20100801

• Role of PPAR gamma/nitric oxide synthase signaling in the cyclosporine-induced attenuation of endothelium-dependent renovascular vasodilation.

  Journal of cardiovascular pharmacology 20100801

• Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100801

• Effect of pioglitazone on endothelial function in impaired glucose tolerance.

  Diabetes, obesity & metabolism 20100801

• Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.

  Diabetes, obesity & metabolism 20100801

• Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.

  Diabetes technology & therapeutics 20100801

• Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.

  Expert opinion on investigational drugs 20100801

• Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation.

  British journal of pharmacology 20100801

• Pioglitazone: beyond glucose control.

  Expert review of cardiovascular therapy 20100801

• Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain.

  Experimental and clinical psychopharmacology 20100801

• Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20100801

• Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study.

  Acta cardiologica 20100801

• Withdrawal of pioglitazone in patients with type 2 diabetes mellitus.

  Journal of clinical pharmacy and therapeutics 20100801

• Application of the DBS methodology to a toxicokinetic study in rats and transferability of analysis between bioanalytical laboratories.

  Bioanalysis 20100801

• Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice.

  Indian journal of experimental biology 20100801

• Rosiglitazone and the case for safety over certainty.

  JAMA 20100728

• Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

  JAMA 20100728

• S961, an insulin receptor antagonist causes hyperinsulinemia, insulin-resistance and depletion of energy stores in rats.

  Biochemical and biophysical research communications 20100723

• Drug safety. Planned study of Avandia in doubt after FDA review.

  Science (New York, N.Y.) 20100723

• Effective approach.

  Nature 20100722

• A consistency-adjusted alpha-adaptive strategy for sequential testing.

  Statistics in medicine 20100710

• Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.

  Clinical science (London, England : 1979) 20100709

• Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.

  Current drug safety 20100702

• Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB.

  Cell biology international 20100701

• Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes.

  Diabetes care 20100701

• Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain.

  Journal of hypertension 20100701

• Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes.

  Diabetes research and clinical practice 20100701

• Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics.

  European journal of clinical investigation 20100701

• Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.

  Expert opinion on pharmacotherapy 20100701

• Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.

  Pakistan journal of pharmaceutical sciences 20100701

• Pioglitazone, a PPAR-gamma ligand inhibited the nicotinamide-streptozotocin induced sperm abnormalities in type-2 diabetic Wistar rats.

  Pakistan journal of pharmaceutical sciences 20100701

• Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).

  Pharmacoepidemiology and drug safety 20100701

• A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.

  Clinical therapeutics 20100701

• Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes.

  Journal of atherosclerosis and thrombosis 20100630

• Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome.

  Fertility and sterility 20100601

• Thiazolidinediones inhibit TNF-alpha-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATc1.

  Shock (Augusta, Ga.) 20100601

• Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

  Metabolism: clinical and experimental 20100601

• Pioglitazone improves endothelium-dependent vasodilation in hypertensive patients with impaired glucose tolerance in part through a decrease in oxidative stress.

  Atherosclerosis 20100601

• Identification of novel metabolic pathways of pioglitazone in hepatocytes: N-glucuronidation of thiazolidinedione ring and sequential ring-opening pathway.

  Drug metabolism and disposition: the biological fate of chemicals 20100601

• Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes.

  Metabolism: clinical and experimental 20100601

• A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.

  Current medical research and opinion 20100601

• Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics.

  Diabetes research and clinical practice 20100601

• Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone.

  The Journal of clinical endocrinology and metabolism 20100601

• Avandia outcome may signal change in epidemiologists' sway.

  Nature medicine 20100601

• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  The New England journal of medicine 20100506

• Regulatory SNP in the RBP4 gene modified the expression in adipocytes and associated with BMI.

  Obesity (Silver Spring, Md.) 20100501

• Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue.

  Obesity (Silver Spring, Md.) 20100501

• Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.

  Atherosclerosis 20100501

• Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20100501

• A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.

  Circulation. Cardiovascular quality and outcomes 20100501

• The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

  American journal of physiology. Heart and circulatory physiology 20100501

• Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats.

  Hepatology (Baltimore, Md.) 20100501

• Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

  The Journal of clinical endocrinology and metabolism 20100501

• Clinical evaluation of combined therapy for type 2 diabetes.

  Current medical research and opinion 20100501

• Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study.

  Echocardiography (Mount Kisco, N.Y.) 20100501

• [Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study].

  Nihon rinsho. Japanese journal of clinical medicine 20100501

• Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants.

  Diabetes/metabolism research and reviews 20100501

• High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone.

  Journal of diabetes science and technology 20100501

• The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease.

  Journal of the American Geriatrics Society 20100501

• Genetic risk factors and the anti-atherosclerotic effect of pioglitazone on carotid atherosclerosis of subjects with type 2 diabetes--a retrospective study.

  Journal of atherosclerosis and thrombosis 20100430

• Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.

  Journal of the American College of Cardiology 20100427

• Letter: Iatrogenic lipomatosis: a rare manifestation of treatment with a peroxisome proliferator-activated receptor gamma agonist.

  Dermatology online journal 20100415

• Peroxisome proliferator-activated receptor-gamma (PPARgamma) modulates hypothalamic Trh regulation in vivo.

  Molecular and cellular endocrinology 20100412

• Calorie control increased vaspin levels of serum and periepididymal adipose tissue in diet-induced obese rats in association with serum free fatty acid and tumor necrosis factor alpha.

  Chinese medical journal 20100405

• Adipophilin affects the expression of TNF-alpha, MCP-1, and IL-6 in THP-1 macrophages.

  Molecular and cellular biochemistry 20100401

• Pioglitazone and mechanisms of CV protection.

  QJM : monthly journal of the Association of Physicians 20100401

• Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment.

  Journal of molecular modeling 20100401

• Effect of pioglitazone on energy intake and ghrelin in diabetic patients.

  Diabetes care 20100401

• Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats.

  Naunyn-Schmiedeberg's archives of pharmacology 20100401

• Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.

  The Journal of clinical endocrinology and metabolism 20100401

• Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.

  Endocrinology 20100401

• Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size.

  Cardiovascular drugs and therapy 20100401

• The nephroprotective effects of pioglitazone and glibenclamide against gentamicin-induced nephrotoxicity in rats: a comparative study.

  Journal of chemotherapy (Florence, Italy) 20100401

• Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.

  Nephrology (Carlton, Vic.) 20100401

• Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients.

  Neuroscience letters 20100326

• Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation.

  European journal of pharmacology 20100310

• Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100301

• Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.

  Liver international : official journal of the International Association for the Study of the Liver 20100301

• Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists.

  Analytical and bioanalytical chemistry 20100301

• Pioglitazone: side effect and safety profile.

  Expert opinion on drug safety 20100301

• [Dementia and insulin resistance in patients with diabetes mellitus].

  Nihon rinsho. Japanese journal of clinical medicine 20100301

• Identification, isolation and characterization of potential degradation products in pioglitazone hydrochloride drug substance.

  Die Pharmazie 20100301

• Evidence against a direct role of klotho in insulin resistance.

  Pflugers Archiv : European journal of physiology 20100201

• Pioglitazone induced reversible pancytopenia.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20100201

• Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.

  Toxicological sciences : an official journal of the Society of Toxicology 20100201

• Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.

  Journal of hypertension 20100201

• Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes.

  Diabetes, obesity & metabolism 20100201

• Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist.

  American journal of physiology. Endocrinology and metabolism 20100201

• 3T3-L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferator-activated receptor-gamma-dependent and mediated by the caspase-3-dependent apoptotic pathway.

  The FEBS journal 20100201

• Lipid metabolism.

  Current opinion in lipidology 20100201

• Effects of peroxisome proliferator-activated receptor gamma agonists on Na+ transport and activity of the kinase SGK1 in epithelial cells from lung and kidney.

  British journal of pharmacology 20100201

• [Glycemic control and cardiovascular benefit: What do we know today?].

  Deutsche medizinische Wochenschrift (1946) 20100201

• [Mechanism of sex differences and the clinical significance of PPARgamma targeted drugs].

  Nihon rinsho. Japanese journal of clinical medicine 20100201

• [Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice].

  Nihon rinsho. Japanese journal of clinical medicine 20100201

• [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].

  Nihon rinsho. Japanese journal of clinical medicine 20100201

• [Anti-vascular failure effects].

  Nihon rinsho. Japanese journal of clinical medicine 20100201

• Biokinetic study of pioglitazone in female volunteers by a validated high performance liquid chromatography method.

  Saudi medical journal 20100201

• Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.

  Diabetic medicine : a journal of the British Diabetic Association 20100201

• Peroxisome proliferator-activated receptor-gamma agonists suppress iNOS expression induced by LPS in rat primary Schwann cells.

  Journal of neuroimmunology 20100125

• Risk of thiazolidinedione-associated fracture should be appropriately assessed.

  Archives of internal medicine 20100125

• Pioglitazone reduces tumor necrosis factor-alpha serum concentration and mRNA expression of adipose tissue in hypercholesterolemic rabbits.

  International journal of cardiology 20100121

• Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.

  International journal of cardiology 20100121

• Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.

  Journal of diabetes and its complications 20100101

• Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.

  Metabolism: clinical and experimental 20100101

• Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.

  Metabolism: clinical and experimental 20100101

• The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus.

  Journal of human hypertension 20100101

• Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor.

  American journal of physiology. Endocrinology and metabolism 20100101

• Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism.

  Arteriosclerosis, thrombosis, and vascular biology 20100101

• Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus.

  The Journal of clinical endocrinology and metabolism 20100101

• Long-term pioglitazone treatment augments insulin sensitivity and PKC-epsilon and PKC-theta activation in skeletal muscles in sucrose fed rats.

  Physiological research 20100101

• Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone.

  Hypertension (Dallas, Tex. : 1979) 20100101

• The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.

  International journal of oncology 20100101

• PPAR-gamma agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-kappaB pathways.

  Immunology and cell biology 20100101

• Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins.

  ASN neuro 20100101

• Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone.

  Diabetes care 20100101

• PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.

  Journal of Korean medical science 20100101

• Human catalase gene is regulated by peroxisome proliferator activated receptor-gamma through a response element distinct from that of mouse.

  Endocrine journal 20100101

• The thiazolidinedione pioglitazone increases cholesterol biosynthetic gene expression in primary cortical neurons by a PPARgamma-independent mechanism.

  Journal of Alzheimer's disease : JAD 20100101

• Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes.

  Endocrine journal 20100101

• Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101

• Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat.

  Diabetes & vascular disease research 20100101

• [Effects of pioglitazone on the transdifferentiation and CTGF expression of renal tubular epithelial-myofibroblast in vitro].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20100101

• A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.

  HIV clinical trials 20100101

• Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.

  Vascular health and risk management 20100101

• Effects of long-term pioglitazone treatment on peripheral and central markers of aging.

  PloS one 20100101

• Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice.

  Biological & pharmaceutical bulletin 20100101

• Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease.

  Congestive heart failure (Greenwich, Conn.) 20100101

• The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.

  BMC infectious diseases 20100101

• Antidiabetic effects of total flavonoids from Litsea Coreana leve on fat-fed, streptozotocin-induced type 2 diabetic rats.

  The American journal of Chinese medicine 20100101

• Rapid HPLC determination of pioglitazone in human plasma by protein precipitation and its application to pharmacokinetic studies.

  Journal of AOAC International 20100101

• Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.

  Endocrine research 20100101

• Does pioglitazone directly influence platelet aggregation?

  Cardiology 20100101

• Effect of pioglitazone on platelet aggregation in a healthy cohort.

  Cardiology 20100101

• Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells.

  Neuroendocrinology 20100101

• Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.

  Vascular health and risk management 20100101

• Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study.

  Cardiovascular diabetology 20100101

• Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis.

  Cardiovascular revascularization medicine : including molecular interventions 20100101

• Targeting CYP450 modulation to decrease the risk of induced cataract in the experimental model.

  Indian journal of ophthalmology 20100101

• Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection.

  PloS one 20100101

• Pioglitazone attenuates allergic inflammation and induces production of regulatory T lymphocytes.

  American journal of rhinology & allergy 20100101

• Insulin resistance is not conserved in myotubes established from women with PCOS.

  PloS one 20100101

• National Diabetes Month: headlines from 2010.

  Diabetes self-management 20100101

• Activation of PPAR gamma induces profound multilocularization of adipocytes in adult mouse white adipose tissues.

  Experimental & molecular medicine 20091231

• Impact of DNA demethylation of the G0S2 gene on the transcription of G0S2 in squamous lung cancer cell lines with or without nuclear receptor agonists.

  Biochemical and biophysical research communications 20091225

• Pioglitazone enhances pyruvate and lactate oxidation in cultured neurons but not in cultured astroglia.

  Brain research 20091211

• PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss.

  Neurochemistry international 20091201

• The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.

  Basic & clinical pharmacology & toxicology 20091201

• Case series of liver failure associated with rosiglitazone and pioglitazone.

  Pharmacoepidemiology and drug safety 20091201

• Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al.

  Pharmacoepidemiology and drug safety 20091201

• CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.

  Fundamental & clinical pharmacology 20091201

• Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.

  Molecular pharmacology 20091201

• Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia.

  European journal of endocrinology 20091201

• Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.

  Diabetes, obesity & metabolism 20091201

• Thiazolidinediones and the liver in humans.

  Current opinion in lipidology 20091201

• Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.

  British journal of haematology 20091201

• Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy.

  Metabolism: clinical and experimental 20091201

• Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.

  Current medical research and opinion 20091201

• Solubility of pioglitazone hydrochloride in aqueous solutions of ethanol, propylene glycol, and N-methyl-2-pyrrolidone at 298.2 degrees K.

  AAPS PharmSciTech 20091201

• Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.

  Current medical research and opinion 20091201

• Adipose tissue collagen VI in obesity.

  The Journal of clinical endocrinology and metabolism 20091201

• Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al.

  Pharmacoepidemiology and drug safety 20091201

• Improving insulin sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of OLETF rats.

  American journal of physiology. Heart and circulatory physiology 20091201

• Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.

  The Journal of clinical endocrinology and metabolism 20091201

• Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20091201

• Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

  Diabetic medicine : a journal of the British Diabetic Association 20091201

• Pioglitazone attenuates ischemia/reperfusion-induced liver injury in rats.

  Transplantation proceedings 20091201

• Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist.

  Archives of dermatology 20091201

• Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment.

  Clinical endocrinology 20091101

• Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

  Diabetes, obesity & metabolism 20091101

• Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice.

  Diabetes 20091101

• Evidence of anti-inflammatory effects of pioglitazone in the murine pleurisy model induced by carrageenan.

  International immunopharmacology 20091101

• Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease.

  American journal of nephrology 20091101

• The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.

  Journal of the American Society of Nephrology : JASN 20091101

• Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients.

  The Journal of clinical endocrinology and metabolism 20091101

• Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20091101

• The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

  Clinical therapeutics 20091101

• Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.

  Journal of diabetes science and technology 20091101

• [Synthesis and preliminary evaluation of antidiabetic activity of 4-(3-(4-bromophenyl)-3-oxo-1-arylpropylamino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide].

  Yao xue xue bao = Acta pharmaceutica Sinica 20091101

• The human lipodystrophy gene product Berardinelli-Seip congenital lipodystrophy 2/seipin plays a key role in adipocyte differentiation.

  Endocrinology 20091001

• Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?

  Diabetes care 20091001

• Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

  Journal of clinical pharmacology 20091001

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

  Current medical research and opinion 20091001

• Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia.

  Fundamental & clinical pharmacology 20091001

• Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?

  Current diabetes reports 20091001

• Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).

  Diabetic medicine : a journal of the British Diabetic Association 20091001

• [Successful treatment of recurrent hypoglycemia by pioglitazone in a patient with myotonic dystrophy].

  Rinsho shinkeigaku = Clinical neurology 20091001

• Rosiglitazone and pioglitazone. Beware fractures.

  BMJ (Clinical research ed.) 20090929

• Rosiglitazone and pioglitazone. Beware macular oedema.

  BMJ (Clinical research ed.) 20090922

• Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.

  Clinical endocrinology 20090901

• Peroxisome proliferator-activated receptor gamma (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults.

  Clinical endocrinology 20090901

• Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes.

  Shock (Augusta, Ga.) 20090901

• Earlier triple therapy with pioglitazone in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20090901

• Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20090901

• Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation.

  Journal of immunology (Baltimore, Md. : 1950) 20090901

• Differential effects of pioglitazone on advanced atherosclerotic lesions.

  The American journal of pathology 20090901

• Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans.

  Arteriosclerosis, thrombosis, and vascular biology 20090901

• Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.

  International journal of clinical practice 20090901

• Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation.

  The Journal of thoracic and cardiovascular surgery 20090901

• [Relationship between insulin resistance and bone metabolism].

  Clinical calcium 20090901

• The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.

  PLoS medicine 20090901

• Rosiglitazone or pioglitazone in type 2 diabetes?

  BMJ (Clinical research ed.) 20090818

• A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats.

  European journal of pharmacology 20090815

• The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

  Journal of immunology (Baltimore, Md. : 1950) 20090815

• Thiazolidinediones and fractures in men and women.

  Archives of internal medicine 20090810

• On the mechanism for PPAR agonists to enhance ABCA1 gene expression.

  Atherosclerosis 20090801

• Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090801

• Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice.

  Endocrinology 20090801

• Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.

  Metabolism: clinical and experimental 20090801

• Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents.

  Pharmacoepidemiology and drug safety 20090801

• Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations.

  Endocrinology 20090801

• Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers.

  Diabetes, obesity & metabolism 20090801

• The role of pioglitazone in modifying the atherogenic lipoprotein profile.

  Diabetes, obesity & metabolism 20090801

• Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes.

  Diabetes research and clinical practice 20090801

• Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients.

  Journal of cardiology 20090801

• Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

  Best practice & research. Clinical endocrinology & metabolism 20090801

• Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).

  The American journal of cardiology 20090715

• Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

  Lancet (London, England) 20090711

• Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.

  Journal of medicinal chemistry 20090709

• Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.

  Atherosclerosis 20090701

• Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation.

  Heart (British Cardiac Society) 20090701

• Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones.

  The Journal of pharmacology and experimental therapeutics 20090701

• PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line.

  American journal of physiology. Renal physiology 20090701

• Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients.

  American journal of physiology. Endocrinology and metabolism 20090701

• Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion.

  American journal of physiology. Gastrointestinal and liver physiology 20090701

• Extraction of trace amounts of pioglitazone as an anti-diabetic drug with hollow fiber liquid phase microextraction and determination by high-performance liquid chromatography-ultraviolet detection in biological fluids.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090701

• Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells.

  Journal of neuropathology and experimental neurology 20090701

• Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction.

  Pharmacotherapy 20090701

• Pioglitazone-induced acute rhabdomyolysis.

  Diabetes care 20090701

• Type 2 diabetes, thiazolidinediones, and cardiovascular risk.

  The British journal of general practice : the journal of the Royal College of General Practitioners 20090701

• Simultaneous determination of metformin hydrochloride and pioglitazone hydrochloride in binary mixture and in their ternary mixture with pioglitazone acid degradate using spectrophotometric and chemometric methods.

  Drug testing and analysis 20090701

• Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.

  Diabetes & vascular disease research 20090701

• A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.

  Journal of neuroimmunology 20090625

• Thiazolidinediones and clinical outcomes in type 2 diabetes.

  Lancet (London, England) 20090620

• Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.

  Clinical endocrinology 20090601

• Mulberry leaf ameliorates the expression profile of adipocytokines by inhibiting oxidative stress in white adipose tissue in db/db mice.

  Atherosclerosis 20090601

• Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs.

  Pulmonary pharmacology & therapeutics 20090601

• Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.

  Diabetes, obesity & metabolism 20090601

• Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.

  Pharmacoepidemiology and drug safety 20090601

• Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2).

  Diabetologia 20090601

• Insulin-dependent actions of pioglitazone in newly diagnosed, drug naïve patients with type 2 diabetes.

  Endocrine 20090601

• Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.

  British journal of pharmacology 20090601

• Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?

  Journal of hepatology 20090601

• A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.

  Current medical research and opinion 20090601

• Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone.

  The American journal of pathology 20090601

• Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20090601

• Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons.

  Journal of neurochemistry 20090601

• PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models.

  Journal of neurochemistry 20090601

• Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.

  Diabetes technology & therapeutics 20090601

• Improved cardiac function after sirolimus-eluting stent placement in diabetic patients by pioglitazone: combination therapy with statin.

  Journal of cardiology 20090601

• Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

  Diabetes, obesity & metabolism 20090601

• Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20090601

• A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).

  JACC. Cardiovascular interventions 20090601

• Pioglitazone to reduce restenosis after bare-metal stent placement?

  JACC. Cardiovascular interventions 20090601

• Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide.

  Experimental lung research 20090601

• Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone.

  Obesity (Silver Spring, Md.) 20090501

• Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice.

  Hepatology (Baltimore, Md.) 20090501

• Translation of basic science into clinical medicine: novel targets for diabetic nephropathy.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090501

• Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages.

  American journal of physiology. Endocrinology and metabolism 20090501

• A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT.

  American journal of physiology. Cell physiology 20090501

• Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.

  The Journal of clinical endocrinology and metabolism 20090501

• Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats.

  European journal of pharmacology 20090501

• Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction.

  American journal of physiology. Heart and circulatory physiology 20090501

• Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.

  Current medical research and opinion 20090501

• Thiazolidinediones: antidiabetic agents with effects on bone.

  Joint, bone, spine : revue du rhumatisme 20090501

• Pioglitazone: more than just an insulin sensitizer.

  Hepatology (Baltimore, Md.) 20090501

• Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome.

  The American journal of psychiatry 20090501

• Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.

  Journal of pediatric gastroenterology and nutrition 20090501

• Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.

  Diabetes, obesity & metabolism 20090501

• Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension.

  International journal of clinical pharmacology and therapeutics 20090501

• Cardiovascular risk and TZD: safe therapy for the elderly?

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20090501

• Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids.

  Diabetic medicine : a journal of the British Diabetic Association 20090501

• PPARgamma stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells.

  Neuroscience letters 20090424

• Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

  Circulation 20090421

• Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.

  Circulation 20090421

• [Role of peroxisome proliferators-activated receptor-gamma in the chemical prevention therapy of sulindac for precancerous lesions of rats].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20090418

• [Role of adiponectin and its receptors in anti-atherosclerotic effects of pioglitazone on ApoE knocked out mice].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20090418

• Thiazolidinedione use and the risk of fractures.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090414

• [Progress in therapy for diabetes mellitus--insulin-resistance ameliorating agents].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090410

• Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome.

  Atherosclerosis 20090401

• Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes.

  Endocrinology 20090401

• Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome.

  Experimental neurology 20090401

• Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.

  The Journal of clinical endocrinology and metabolism 20090401

• Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.

  Journal of the American Society of Nephrology : JASN 20090401

• Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.

  Diabetologia 20090401

• Glitazone use associated with diabetic macular edema.

  American journal of ophthalmology 20090401

• Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice.

  Diabetologia 20090401

• Pioglitazone-induced heart failure in a patient with restrictive cardiomyopathy and metabolic myopathy.

  Clinical research in cardiology : official journal of the German Cardiac Society 20090401

• Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report.

  Diabetes & metabolism 20090401

• Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.

  Diabetes, obesity & metabolism 20090401

• Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.

  Journal of internal medicine 20090401

• Autoradiographical imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice.

  Experimental neurology 20090401

• Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.

  Journal of pediatric and adolescent gynecology 20090401

• Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial.

  Archives of dermatology 20090401

• Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.

  Singapore medical journal 20090401

• Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake.

  Nephrology (Carlton, Vic.) 20090401

• [Insulin sensitizing drugs].

  Vnitrni lekarstvi 20090401

• The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.

  Trends in cardiovascular medicine 20090401

• Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting.

  Swiss medical weekly 20090321

• Effect of Tectona grandis Linn. on dexamethasone-induced insulin resistance in mice.

  Journal of ethnopharmacology 20090318

• A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome.

  Fertility and sterility 20090301

• Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes.

  Acta diabetologica 20090301

• Pioglitazone reduces monocyte activation in type 2 diabetes.

  Acta diabetologica 20090301

• The effects of hydroxycinnamic acid derivatives on adiponectin secretion.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20090301

• Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids.

  American journal of physiology. Endocrinology and metabolism 20090301

• Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation.

  Journal of hepatology 20090301

• Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.

  Metabolism: clinical and experimental 20090301

• Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090301

• DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.

  Advances in therapy 20090301

• Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20090301

• Flow-injection chemiluminometric determination of pioglitazone HCl by its sensitizing effect on the cerium-sulfite reaction.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20090301

• Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils.

  Journal of pharmacological sciences 20090301

• Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20090301

• PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia.

  Biochemical and biophysical research communications 20090227

• Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease.

  Behavioural brain research 20090211

• Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.

  Clinical endocrinology 20090201

• Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

  The Journal of clinical endocrinology and metabolism 20090201

• Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.

  Clinica chimica acta; international journal of clinical chemistry 20090201

• BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner.

  American journal of physiology. Cell physiology 20090201

• Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.

  Diabetes/metabolism research and reviews 20090201

• Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus.

  Circulation journal : official journal of the Japanese Circulation Society 20090201

• Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

  Diabetes/metabolism research and reviews 20090201

• Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).

  Diabetic medicine : a journal of the British Diabetic Association 20090201

• Adverse effect of pioglitazone in military personnel and their families: a preliminary report.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090201

• TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis.

  Biochemical and biophysical research communications 20090130

• The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.

  International journal of cardiology 20090124

• The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.

  European journal of pharmacology 20090114

• Thiazolidinediones: do harms outweigh benefits?

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090106

• Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090106

• Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

  Diabetes, obesity & metabolism 20090101

• Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).

  Atherosclerosis 20090101

• Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

• Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.

  Heart (British Cardiac Society) 20090101

• Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

  Contemporary clinical trials 20090101

• Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis.

  Respiration; international review of thoracic diseases 20090101

• Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.

  Hepatology (Baltimore, Md.) 20090101

• Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.

  Molecular cancer therapeutics 20090101

• Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.

  Cardiovascular revascularization medicine : including molecular interventions 20090101

• Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus.

  Journal of the American Geriatrics Society 20090101

• Effects of thiazolidinediones beyond glycaemic control.

  Current pharmaceutical design 20090101

• Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.

  Clinical therapeutics 20090101

• Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.

  Internal medicine (Tokyo, Japan) 20090101

• EPC adhesion to arteries from diabetic and non-diabetic patients: effect of pioglitazone.

  Frontiers in bioscience (Landmark edition) 20090101

• Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes.

  Cardiovascular diabetology 20090101

• Effect of pioglitazone on sciatic nerve ischemia/reperfusion injury in rats.

  Pediatric neurosurgery 20090101

• Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.

  Drug safety 20090101

• Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study.

  Drug safety 20090101

• Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial.

  Endocrine journal 20090101

• Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding.

  Advances in medical sciences 20090101

• Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.

  Drug safety 20090101

• Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.

  Cardiovascular therapeutics 20090101

• Redefining the role of thiazolidinediones in the management of type 2 diabetes.

  Vascular health and risk management 20090101

• Safety and efficacy of rosiglitazone in the elderly diabetic patient.

  Vascular health and risk management 20090101

• Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy.

  Endocrine journal 20090101

• Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy.

  Endocrine journal 20090101

• Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes.

  Endocrine journal 20090101

• Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo.

  Journal of gastroenterology 20090101

• Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells.

  Vascular pharmacology 20090101

• Pioglitazone might prevent the progression of slowly progressive type 1 diabetes.

  Internal medicine (Tokyo, Japan) 20090101

• Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.

  Endocrine research 20090101

• Rosiglitazone and myocardial infarction in patients previously prescribed metformin.

  PloS one 20090101

• Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.

  PloS one 20090101

• Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.

  Drug safety 20090101

• Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.

  Drug safety 20090101

• Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

  BMJ (Clinical research ed.) 20090101

• Pioglitazone induced gastric acid secretion.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20090101

• Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation.

  Cardiovascular diabetology 20090101

• A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes.

  Endocrine journal 20090101

• Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice.

  Pharmacology 20090101

• Pioglitazone reduces ER stress in the liver: direct monitoring of in vivo ER stress using ER stress-activated indicator transgenic mice.

  Endocrine journal 20090101

• Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.

  Endocrine research 20090101

• Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study.

  Clinical laboratory 20090101

• Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts.

  Molecular vision 20090101

• Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

  BMJ (Clinical research ed.) 20090101

• The effect of pioglitazone on the liver of streptozotocin-induced diabetic albino Wistar rats.

  European review for medical and pharmacological sciences 20090101

• Primary pioglitazone failure in Asian Indian diabetics is not related to common Pro12Ala polymorph of PPAR-gamma gene.

  Indian journal of physiology and pharmacology 20090101

• Involvement of hyperglycemia in deposition of aggregated protein in glomeruli of diabetic mice.

  European journal of pharmacology 20081228

• Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.

  Diabetes, obesity & metabolism 20081201

• Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

  Diabetes, obesity & metabolism 20081201

• Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line.

  Biology of the cell 20081201

• A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes.

  Journal of lipid research 20081201

• Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.

  Clinical and experimental pharmacology & physiology 20081201

• Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance.

  Arteriosclerosis, thrombosis, and vascular biology 20081201

• Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone.

  Cardiovascular drugs and therapy 20081201

• Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone?

  Diabetes research and clinical practice 20081201

• Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice.

  American journal of physiology. Heart and circulatory physiology 20081201

• Long-term pioglitazone treatment enhances lipolysis in rat adipose tissue.

  International journal of obesity (2005) 20081201

• Lipid lowering in diabetes mellitus.

  Current opinion in lipidology 20081201

• Conduct disorder in an adolescent girl treated with an insulin-sensitizing agent.

  Psychiatry and clinical neurosciences 20081201

• Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes.

  Geriatrics & gerontology international 20081201

• Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.

  Vascular health and risk management 20081201

• [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].

  Medicina clinica 20081129

• Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

  Archives of internal medicine 20081124

• Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3'-kinase.

  Life sciences 20081107

• Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?

  Diabetes, obesity & metabolism 20081101

• Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.

  Atherosclerosis 20081101

• Stearoyl-coenzyme A desaturase 1 gene expression increases after pioglitazone treatment and is associated with peroxisomal proliferator-activated receptor-gamma responsiveness.

  The Journal of clinical endocrinology and metabolism 20081101

• Fatty acid metabolism in patients with PPARgamma mutations.

  The Journal of clinical endocrinology and metabolism 20081101

• Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production.

  American journal of physiology. Endocrinology and metabolism 20081101

• Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.

  Diabetologia 20081101

• The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.

  Diabetes research and clinical practice 20081101

• Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.

  Current medical research and opinion 20081101

• Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide.

  Current medical research and opinion 20081101

• Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

  Metabolism: clinical and experimental 20081101

• Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.

  Diabetes & vascular disease research 20081101

• PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes.

  Diabetes & vascular disease research 20081101

• Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.

  The European journal of neuroscience 20081101

• Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel.

  Journal of pharmacological sciences 20081101

• Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury.

  Journal of pharmacological sciences 20081101

• Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats.

  Journal of cardiovascular pharmacology 20081101

• [Mechanism of BVT.2733 and pioglitazone in the improvement of insulin resistance].

  Zhonghua nei ke za zhi 20081101

• Severe acanthosis nigricans in a 17 year-old female with partial lipodystrophic syndrome.

  Journal of pediatric endocrinology & metabolism : JPEM 20081101

• Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease.

  Clinical research in cardiology : official journal of the German Cardiac Society 20081001

• Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts.

  Inflammatory bowel diseases 20081001

• Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue.

  American journal of physiology. Endocrinology and metabolism 20081001

• Rosiglitazone and cardiovascular risk.

  Current atherosclerosis reports 20081001

• Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.

  Gastroenterology 20081001

• Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes.

  Chemical research in toxicology 20081001

• Does pioglitazone provide a better renoprotective effect than insulin in diabetic patients?

  Kidney international 20081001

• Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081001

• Reduced prehepatic extraction of nicardipine in the presence of pioglitazone in rats.

  The Journal of pharmacy and pharmacology 20081001

• Simultaneous determination of pioglitazone and glimepiride in bulk drug and pharmaceutical dosage form by RP-HPLC method.

  Pakistan journal of pharmaceutical sciences 20081001

• On identification of the number of best treatments using the Newman-Keuls test.

  Biometrical journal. Biometrische Zeitschrift 20081001

• [Current evidence-based medicine for early intervention in diabetes].

  Nihon rinsho. Japanese journal of clinical medicine 20081001

• Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction.

  Experimental animals 20081001

• Development and validation of a simple and rapid HPLC method for determination of pioglitazone in human plasma and its application to a pharmacokinetic study.

  Journal of chromatographic science 20081001

• Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study.

  Vascular health and risk management 20081001

• New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies.

  Bioorganic & medicinal chemistry letters 20080915

• Characteristics of new composite- and classical potentiometric sensors for the determination of pioglitazone in some pharmaceutical formulations.

  Journal of pharmaceutical and biomedical analysis 20080910

• Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080910

• The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

  Journal of the American College of Cardiology 20080902

• Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-alpha activation make the difference?

  Journal of the American College of Cardiology 20080902

• Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.

  Diabetes, obesity & metabolism 20080901

• Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.

  Clinical endocrinology 20080901

• Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080901

• Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome.

  Fertility and sterility 20080901

• Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080901

• The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes.

  Diabetes, obesity & metabolism 20080901

• Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.

  Diabetes 20080901

• Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.

  Diabetes 20080901

• Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability.

  Archives of biochemistry and biophysics 20080901

• Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.

  The Journal of clinical endocrinology and metabolism 20080901

• Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.

  Journal of molecular graphics & modelling 20080901

• Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients.

  Diabetes research and clinical practice 20080901

• Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes.

  American journal of physiology. Heart and circulatory physiology 20080901

• Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20080901

• The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

  Expert opinion on pharmacotherapy 20080901

• Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production.

  Journal of immunology (Baltimore, Md. : 1950) 20080901

• Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.

  Journal of pharmacological sciences 20080901

• Reassessing the cardiovascular risks and benefits of thiazolidinediones.

  Clinical cardiology 20080901

• Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis.

  Clinical nephrology 20080901

• Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats.

  Archives of pharmacal research 20080901

• Pioglitazone promotes peripheral nerve remyelination after crush injury through CD36 upregulation.

  Journal of the peripheral nervous system : JPNS 20080901

• Suppression of post-prandial hyperglycaemia by pioglitazone improved islet fibrosis and macrophage migration in the Goto-Kakizaki rat.

  Diabetes, obesity & metabolism 20080901

• Extension of the life span in patients with Werner syndrome.

  Journal of the American Geriatrics Society 20080901

• [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].

  MMW Fortschritte der Medizin 20080828

• Small-interference RNA-mediated knock-down of aldehyde oxidase 1 in 3T3-L1 cells impairs adipogenesis and adiponectin release.

  FEBS letters 20080820

• Pioglitazone vs glimepiride in the PERISCOPE trial.

  JAMA 20080820

• Pioglitazone vs glimepiride in the PERISCOPE trial.

  JAMA 20080820

• PGC-1alpha integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle.

  The Journal of biological chemistry 20080815

• Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis.

  Neuropathology : official journal of the Japanese Society of Neuropathology 20080801

• A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080801

• Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.

  Pharmacoepidemiology and drug safety 20080801

• Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of rat.

  Cardiovascular drugs and therapy 20080801

• Pioglitazone does not affect vascular or inflammatory responses after endotoxemia in humans.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20080801

• Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients.

  British journal of clinical pharmacology 20080801

• Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines.

  American journal of physiology. Endocrinology and metabolism 20080801

• Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.

  Journal of hepatology 20080801

• Are prescribing patterns of antidiabetic medications influenced by fears of litigation?

  Nature clinical practice. Endocrinology & metabolism 20080801

• Combination therapy for treatment or prevention of atherosclerosis.

  Hypertension (Dallas, Tex. : 1979) 20080801

• Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease.

  Coronary artery disease 20080801

• Association between serious ischemic cardiac outcomes and medications used to treat diabetes.

  Pharmacoepidemiology and drug safety 20080801

• Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt.

  Journal of hypertension 20080801

• Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system.

  Metabolism: clinical and experimental 20080801

• Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers.

  Metabolism: clinical and experimental 20080801

• Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction.

  Journal of cardiac failure 20080801

• [Pioglitazone effects on blood pressure in patients with metabolic syndrome].

  Nihon rinsho. Japanese journal of clinical medicine 20080801

• A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.

  Current medical research and opinion 20080801

• Massive bilateral pleural effusion associated with use of pioglitazone.

  Clinical therapeutics 20080801

• Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells.

  Diabetes, obesity & metabolism 20080701

• Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.

  Atherosclerosis 20080701

• Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.

  Intensive care medicine 20080701

• Age-dependent development of metabolic derangement and effects of intervention with pioglitazone in Zucker diabetic fatty rats.

  The Journal of pharmacology and experimental therapeutics 20080701

• Metabolic recovery of adipose tissue is associated with improvement in insulin resistance in a model of experimental diabetes.

  The Journal of endocrinology 20080701

• Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone.

  Diabetes research and clinical practice 20080701

• Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes.

  Endocrine journal 20080701

• Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor.

  Journal of immunology (Baltimore, Md. : 1950) 20080701

• Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease.

  Circulation journal : official journal of the Japanese Circulation Society 20080701

• The cardiovascular safety of rosiglitazone.

  Expert opinion on drug safety 20080701

• Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation.

  Journal of chromatographic science 20080701

• Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

  International journal of clinical pharmacology and therapeutics 20080701

• Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo.

  Biochemical and biophysical research communications 20080627

• The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20080601

• PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo.

  Investigational new drugs 20080601

• Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand.

  Naunyn-Schmiedeberg's archives of pharmacology 20080601

• Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis.

  Diabetes research and clinical practice 20080601

• The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.

  Diabetes technology & therapeutics 20080601

• New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies.

  Bioorganic & medicinal chemistry letters 20080601

• Effect of pioglitazone on nitroglycerin-induced impairment of nitric oxide bioavailability by a catheter-type nitric oxide sensor.

  Circulation journal : official journal of the Japanese Circulation Society 20080601

• Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer.

  Neoplasia (New York, N.Y.) 20080601

• Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats.

  Journal of gastroenterology and hepatology 20080601

• Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma.

  PLoS genetics 20080601

• Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.

  Brain research 20080507

• Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.

  Clinical endocrinology 20080501

• Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARgamma agonist pioglitazone.

  Pflugers Archiv : European journal of physiology 20080501

• Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats.

  Obesity (Silver Spring, Md.) 20080501

• Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial.

  The Journal of clinical endocrinology and metabolism 20080501

• The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.

  British journal of pharmacology 20080501

• The Effect of pioglitazone on circulating adiponectin is highly predictable based on its basal level.

  Diabetes research and clinical practice 20080501

• Pleiotropic effects of thiazolidinediones.

  Expert opinion on pharmacotherapy 20080501

• Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders.

  Journal of molecular and cellular cardiology 20080501

• Initiating antidiabetic drug therapy.

  Clinical therapeutics 20080501

• Protective effects of a PPARgamma agonist pioglitazone on anti-oxidative system in testis of diabetic rabbits.

  Die Pharmazie 20080501

• Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.

  Current clinical pharmacology 20080501

• Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.

  Circulation 20080422

• Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition.

  Biochemical pharmacology 20080415

• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

  JAMA 20080402

• Does PERISCOPE provide a new perspective on diabetic treatment?

  JAMA 20080402

• Effect of aspirin use on thiazolidinediones and cardiovascular events.

  JAMA 20080402

• Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting.

  Atherosclerosis 20080401

• Assessment of genotoxicity in rats treated with the antidiabetic agent, pioglitazone.

  Environmental and molecular mutagenesis 20080401

• Keishibukuryogan ameliorates glucose intolerance and hyperlipidemia in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.

  Diabetes research and clinical practice 20080401

• Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia.

  British journal of pharmacology 20080401

• Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs.

  Diabetologia 20080401

• High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects.

  Journal of internal medicine 20080401

• Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.

  Diabetes, obesity & metabolism 20080401

• Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.

  The American journal of cardiology 20080401

• Role of pioglitazone treatment on atrial remodeling and atrial fibrillation (AF)promotion in an experimental model of congestive heart failure.

  Heart rhythm 20080401

• Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

  American heart journal 20080401

• PROactive: time for a critical appraisal.

  European heart journal 20080401

• Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathway.

  Journal of pharmacological sciences 20080401

• Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.

  Current atherosclerosis reports 20080401

• PPARgamma agonists and coronary atherosclerosis.

  Current atherosclerosis reports 20080401

• Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080401

• Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080401

• [Pioglitazone inhibits dendritic cell adhesion and transmigration through down-regulation of dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin].

  Zhonghua yi xue za zhi 20080325

• Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway.

  Life sciences 20080312

• Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease.

  Atherosclerosis 20080301

• Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes.

  Acta diabetologica 20080301

• 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.

  Diabetes research and clinical practice 20080301

• Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.

  Acta diabetologica 20080301

• Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.

  Clinical journal of the American Society of Nephrology : CJASN 20080301

• Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.

  Archiv der Pharmazie 20080301

• Consensus on infertility treatment related to polycystic ovary syndrome.

  Human reproduction (Oxford, England) 20080301

• Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.

  Heart rhythm 20080301

• Heart failure-related atrial fibrillation: a new model for a new prevention strategy?

  Heart rhythm 20080301

• Vaspin: a novel serpin with insulin-sensitizing effects.

  Expert opinion on investigational drugs 20080301

• Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats.

  Neuroscience letters 20080227

• Clinical decisions. Management of type 2 diabetes--polling results.

  The New England journal of medicine 20080214

• Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice.

  Circulation 20080212

• Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells.

  Fertility and sterility 20080201

• Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome.

  Clinical endocrinology 20080201

• Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.

  Diabetes 20080201

• Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.

  Diabetes care 20080201

• Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.

  Clinical endocrinology 20080201

• Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.

  Hypertension (Dallas, Tex. : 1979) 20080201

• The ratio of leptin to adiponectin can be used as an index of insulin resistance.

  Metabolism: clinical and experimental 20080201

• Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.

  Expert opinion on pharmacotherapy 20080201

• Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

  Expert opinion on pharmacotherapy 20080201

• [Glitazone - mailing no 2. In response to DMW 49/2007].

  Deutsche medizinische Wochenschrift (1946) 20080201

• [Glitazone - mailing no 4. In response to DMW 49/2007].

  Deutsche medizinische Wochenschrift (1946) 20080201

• Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients.

  Journal of atherosclerosis and thrombosis 20080201

• Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.

  Minerva ginecologica 20080201

• Pioglitazone and losartan modify hemodynamic and metabolic parameters and vascular prostanoids in fructose-overloaded rats.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20080201

• Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080201

• Synthesis of polymeric thiazolidinedione and fibrate conjugates.

  Archives of pharmacal research 20080201

• Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.

  Endocrine 20080201

• Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid.

  Life sciences 20080130

• Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance.

  Biochemical and biophysical research communications 20080118

• Clinical decisions. Management of type 2 diabetes.

  The New England journal of medicine 20080117

• Thiazolinediones and heart failure: the potential to precipitate irreversible cardiac dysfunction.

  International journal of cardiology 20080111

• Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE.

  Journal of pharmaceutical and biomedical analysis 20080107

• No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.

  British journal of clinical pharmacology 20080101

• Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101

• Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.

  Diabetes care 20080101

• Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.

  Drug metabolism and disposition: the biological fate of chemicals 20080101

• Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.

  Diabetes 20080101

• Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.

  Diabetes/metabolism research and reviews 20080101

• Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats.

  Journal of neurochemistry 20080101

• Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.

  Diabetes, obesity & metabolism 20080101

• Peroxisome proliferator-activated receptor-gamma agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts.

  Clinical and experimental pharmacology & physiology 20080101

• Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.

  Journal of the American Society of Nephrology : JASN 20080101

• Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint.

  American journal of obstetrics and gynecology 20080101

• Early amelioration of insulin resistance and reduction of interleukin-6 in Werner syndrome using pioglitazone.

  Journal of the American Geriatrics Society 20080101

• Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidine (TZDs).

  The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20080101

• Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.

  Arthritis research & therapy 20080101

• Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt.

  Journal of neuroinflammation 20080101

• PPARgamma agonist pioglitazone reduces [corrected] neuronal cell damage after transient global cerebral ischemia through matrix metalloproteinase inhibition.

  The European journal of neuroscience 20080101

• The value equation for rosiglitazone and pioglitazone in older persons.

  Geriatric nursing (New York, N.Y.) 20080101

• Pioglitazone can downregulate bone morphogenetic protein-2 expression induced by high glucose in human umbilical vein endothelial cells.

  Pharmacology 20080101

• Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.

  Acta biochimica Polonica 20080101

• Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice.

  Reproductive biology and endocrinology : RB&E 20080101

• Effects of pioglitazone on nitric oxide bioavailability measured using a catheter-type nitric oxide sensor in angiotensin II-infusion rabbit.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080101

• Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).

  Antiviral therapy 20080101

• Treatment with pioglitazone induced significant, reversible mitral regurgitation.

  Cardiovascular diabetology 20080101

• Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20080101

• Activation of PPARgamma reverses a defect of surfactant synthesis in mice lacking two types of fatty acid binding protein.

  Biochimica et biophysica acta 20080101

• Effect of the Pro12Ala polymorphism of the PPAR gamma 2 gene on response to pioglitazone treatment in menopausal women.

  Menopause (New York, N.Y.) 20080101

• Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome.

  PloS one 20080101

• PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes.

  Cardiovascular journal of Africa 20080101

• Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes.

  Internal medicine (Tokyo, Japan) 20080101

• Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

  Journal of managed care pharmacy : JMCP 20080101

• Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.

  Drug safety 20080101

• PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis.

  Angiogenesis 20080101

• Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet.

  BMC molecular biology 20080101

• Cardiovascular risk and cardiometabolic protection: role of glitazones.

  Journal of nephrology 20080101

• The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus.

  Journal of the cardiometabolic syndrome 20080101

• Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.

  Current topics in medicinal chemistry 20080101

• Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.

  American journal of therapeutics 20080101

• Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis.

  Anticancer research 20080101

• Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.

  JAMA 20071212

• [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].

  MMW Fortschritte der Medizin 20071206

• Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.

  Digestive diseases and sciences 20071201

• Effect of pioglitazone therapy in lean type 1 diabetes mellitus.

  Diabetes research and clinical practice 20071201

• Pioglitazone: an anti-diabetic compound with anti-aging properties.

  Biogerontology 20071201

• Enhanced insulin-hypoglycemic activity in rats consuming a specific glycoprotein extracted from maitake mushroom.

  Molecular and cellular biochemistry 20071201

• Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension.

  European journal of pharmacology 20071201

• Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.

  Kidney international 20071201

• Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice.

  Journal of hepatology 20071201

• Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity.

  Journal of neuroimmunology 20071201

• Use of insulin sensitizers in NASH.

  Endocrinology and metabolism clinics of North America 20071201

• Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial.

  Melanoma research 20071201

• Studies of diabetes, thiazolidinediones, and coronary heart disease.

  Pharmacoepidemiology and drug safety 20071201

• [Therapy with glitazones--a risk for cardiovascular disease?].

  Deutsche medizinische Wochenschrift (1946) 20071201

• [Determining the current position regarding the value of pioglitazone for the therapy of diabetes].

  Deutsche medizinische Wochenschrift (1946) 20071201

• DPP-4 inhibitors.

  Best practice & research. Clinical endocrinology & metabolism 20071201

• Cardiovascular risk in women with polycystic ovary syndrome.

  Minerva endocrinologica 20071201

• Comparative study on the bioequivalence of two formulations of pioglitazone tablet in healthy Thai male volunteers.

  Drug development and industrial pharmacy 20071201

• Pioglitazone inhibits hypertrophy induced by high glucose and insulin in cultured neonatal rat cardiomyocytes.

  Die Pharmazie 20071201

• Glitazones and your heart, revisited.

  Diabetes forecast 20071201

• Rosiglitazone and the thiazolidinediones: a changing context.

  Primary care diabetes 20071201

• Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.

  Journal of the American College of Cardiology 20071120

• Physiologic straws in the wind: in which direction do they bend?

  Journal of the American College of Cardiology 20071120

• [Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].

  Ugeskrift for laeger 20071119

• Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.

  Circulation 20071106

• Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content.

  Atherosclerosis 20071101

• Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

  Diabetes care 20071101

• Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.

  Arteriosclerosis, thrombosis, and vascular biology 20071101

• Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure.

  Stroke 20071101

• Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.

  Diabetes, obesity & metabolism 20071101

• Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report.

  Diabetes & metabolism 20071101

• Treatment of necrobiosis lipoidica with pioglitazone.

  Journal of the American Academy of Dermatology 20071101

• Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line.

  Metabolism: clinical and experimental 20071101

• Elevated plasma adiponectin and leptin levels in sisters with genetically defective insulin receptors.

  Diabetes care 20071101

• Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus 'off-target' effectors.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071101

• Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.

  Fundamental & clinical pharmacology 20071101

• Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.

  Fundamental & clinical pharmacology 20071101

• Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.

  Clinical nephrology 20071101

• Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.

  Mini reviews in medicinal chemistry 20071101

• [Adverse effects of insulin sensitisers and biguanides].

  Nihon rinsho. Japanese journal of clinical medicine 20071028

• A perspective on coronary revascularization in the PROactive 05 study.

  Journal of the American College of Cardiology 20071023

• Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferator-activated receptor-gamma activation in +db/+m and +db/+db mice.

  European journal of pharmacology 20071015

• Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy.

  Biochemical and biophysical research communications 20071005

• Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.

  Atherosclerosis 20071001

• Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.

  Journal of hepatology 20071001

• Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.

  Diabetes care 20071001

• The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.

  Diabetes 20071001

• Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071001

• Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone.

  BJU international 20071001

• Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.

  American journal of physiology. Renal physiology 20071001

• A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.

  Pharmacoepidemiology and drug safety 20071001

• In clarification.

  Pharmacoepidemiology and drug safety 20071001

• Brain endothelial PPARgamma controls inflammation-induced CD4+ T cell adhesion and transmigration in vitro.

  Journal of neuroimmunology 20071001

• Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.

  Oncology reports 20071001

• Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20071001

• Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.

  Pharmacotherapy 20071001

• Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution.

  Journal of pharmacological sciences 20071001

• Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies.

  Journal of pharmacological sciences 20071001

• Indicators for the efficacy of pioglitazone before and during treatment in Japanese patients with type 2 diabetes.

  Diabetes technology & therapeutics 20071001

• Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20071001

• Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20071001

• Does pioglitazone benefit patients with type 2 diabetes?

  American family physician 20071001

• [Glitazones in type 2 diabetes--documented risks, uncertain benefits].

  Lakartidningen 20071001

• [Glitazones more than hypoglycemics in type 2 diabetes].

  Lakartidningen 20071001

• A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

  Vascular health and risk management 20071001

• Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

  Lancet (London, England) 20070929

• Diabetes drug pioglitazone (Actos): risk of fracture.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20070925

• Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.

  Toxicology and applied pharmacology 20070915

• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  JAMA 20070912

• Cardiovascular risk and the thiazolidinediones: déjà vu all over again?

  JAMA 20070912

• MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone.

  Proceedings of the National Academy of Sciences of the United States of America 20070904

• Pharmacologic approaches to restenosis prevention.

  The American journal of cardiology 20070903

• Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders.

  Diabetes research and clinical practice 20070901

• Oral pioglitazone administration increases food intake through ghrelin-independent pathway in Zucker fatty rat.

  Diabetes research and clinical practice 20070901

• Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus.

  Clinical pharmacology and therapeutics 20070901

• Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20070901

• Cytotoxicity of peroxisome proliferator-activated receptor alpha and gamma agonists in renal proximal tubular cell lines.

  Toxicology in vitro : an international journal published in association with BIBRA 20070901

• PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

  Diabetic medicine : a journal of the British Diabetic Association 20070901

• Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.

  European journal of clinical investigation 20070901

• Effects of pioglitazone on lipid and lipoprotein metabolism.

  Diabetes, obesity & metabolism 20070901

• The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.

  Metabolism: clinical and experimental 20070901

• Future directions for insulin sensitizers in disease prevention.

  Current opinion in investigational drugs (London, England : 2000) 20070901

• Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20070901

• A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.

  Diabetes & vascular disease research 20070901

• Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes.

  Diabetes & vascular disease research 20070901

• The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?

  Diabetes & vascular disease research 20070901

• The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes mellitus rats.

  International heart journal 20070901

• [The mechanism of and relationship between lipid metabolism genes expression and insulin resistance in high fat-fed mice].

  Zhonghua nei ke za zhi 20070901

• Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070901

• [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].

  MMW Fortschritte der Medizin 20070802

• The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes.

  Atherosclerosis 20070801

• Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.

  Carcinogenesis 20070801

• Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

  Diabetologia 20070801

• The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.

  Hepatology (Baltimore, Md.) 20070801

• The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20070801

• Treatment of antipsychotic-associated hyperglycemia with pioglitazone: a case series.

  Journal of clinical psychopharmacology 20070801

• Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes.

  Endocrine journal 20070801

• Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2.

  Prostaglandins & other lipid mediators 20070801

• Modulation of cholesterol homeostasis by antiproliferative drugs in human pterygium fibroblasts.

  Investigative ophthalmology & visual science 20070801

• Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.

  Expert opinion on pharmacotherapy 20070801

• Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.

  Diabetes technology & therapeutics 20070801

• Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes.

  Current medical research and opinion 20070801

• Heart failure risk prompts warning labels on diabetes drugs. The concern now is whether this particular class of drugs causes other cardiovascular problems.

  Harvard women's health watch 20070801

• Pioglitazone impurities.

  Die Pharmazie 20070801

• [The changes of TSP-1 expression in the retina of STZ-induced rat diabetic mellitus model with pioglitazone].

  Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology 20070801

• [The relationship between islet alpha cell insulin resistance and inflammatory pathway activation and its mechanism].

  Zhonghua nei ke za zhi 20070801

• PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.

  Vascular health and risk management 20070801

• Initiating insulin in patients with type 2 diabetes.

  The Journal of family practice 20070801

• A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies.

  Journal of neuroscience methods 20070730

• Thiazolidinediones and cardiovascular disease.

  The Medical letter on drugs and therapeutics 20070716

• Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.

  Diabetes/metabolism research and reviews 20070701

• Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.

  Fertility and sterility 20070701

• Retinol binding protein-4 levels and clinical features of type 2 diabetes patients.

  The Journal of clinical endocrinology and metabolism 20070701

• Replicate study design in bioequivalency assessment, pros and cons: bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation.

  Journal of clinical pharmacology 20070701

• Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders?

  American journal of physiology. Gastrointestinal and liver physiology 20070701

• Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.

  International journal of clinical practice 20070701

• The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats.

  Diabetes/metabolism research and reviews 20070701

• [Status of glitazones in treatment of type 2 diabetes mellitus].

  Der Internist 20070701

• The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.

  European journal of cancer (Oxford, England : 1990) 20070701

• Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.

  Diabetes, obesity & metabolism 20070701

• Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes.

  Diabetes, obesity & metabolism 20070701

• Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.

  The Journal of clinical endocrinology and metabolism 20070701

• The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways.

  Arthritis and rheumatism 20070701

• Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20070701

• Options sought after drug study. Patients who take rosiglitazone might consider pioglitazone instead.

  Heart advisor 20070701

• Pioglitazone and metformin.

  Drugs of today (Barcelona, Spain : 1998) 20070701

• Pioglitazone hydrochloride/glimepiride.

  Drugs of today (Barcelona, Spain : 1998) 20070701

• Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20070701

• [A new case: pioglitazone hepatotoxicity].

  Medicina clinica 20070623

• Wnt-signaling is maintained and adipogenesis inhibited by TNFalpha but not MCP-1 and resistin.

  Biochemical and biophysical research communications 20070608

• Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells.

  The Journal of clinical endocrinology and metabolism 20070601

• The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells.

  Molecular pharmacology 20070601

• Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.

  Molecular pharmacology 20070601

• Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.

  Anti-cancer drugs 20070601

• The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury.

  Experimental neurology 20070601

• PPAR-gamma agonist protects podocytes from injury.

  Kidney international 20070601

• Pioglitazone rapidly increases serum adiponectin levels in men with normal glucose tolerance.

  Diabetes care 20070601

• Effects of pioglitazone on stearoyl-CoA desaturase in obese Zucker fa/fa rats.

  Journal of pharmacological sciences 20070601

• Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-gamma and transforming growth factor-beta1.

  Thrombosis and haemostasis 20070601

• [Effect of ligand pioglitazone activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro and the expression regulation of related genes].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20070601

• Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.

  International journal of clinical practice. Supplement 20070601

• Pioglitazone plus glimepiride: a promising alternative in metabolic control.

  International journal of clinical practice. Supplement 20070601

• Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20070601

• Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.

  Canadian journal of physiology and pharmacology 20070601

• Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.

  Clinical therapeutics 20070601

• Hospital admission associated with Medicare Part D 'doughnut hole'.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070515

• The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells.

  Atherosclerosis 20070501

• Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice.

  Atherosclerosis 20070501

• Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070501

• Beta-cell preservation with thiazolidinediones.

  Diabetes research and clinical practice 20070501

• Thiazolidinediones and the risk of edema: a meta-analysis.

  Diabetes research and clinical practice 20070501

• Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan.

  Diabetes research and clinical practice 20070501

• Synergistic effects of pravastatin and pioglitazone in renal tubular epithelial cells induced by transforming growth factor-beta1.

  Cell biology international 20070501

• Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.

  American journal of physiology. Endocrinology and metabolism 20070501

• Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway.

  The Journal of pharmacology and experimental therapeutics 20070501

• Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.

  The Journal of clinical endocrinology and metabolism 20070501

• The effect of beta-adrenergic and peroxisome proliferator-activated receptor-gamma stimulation on target genes related to lipid metabolism in human subcutaneous adipose tissue.

  Diabetes care 20070501

• PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.

  Pharmacological research 20070501

• Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.

  International journal of oncology 20070501

• Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.

  Diabetes, obesity & metabolism 20070501

• Weight gain in type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20070501

• PPAR-gamma: therapeutic target for ischemic stroke.

  Trends in pharmacological sciences 20070501

• Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.

  American heart journal 20070501

• Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease.

  Journal of thrombosis and haemostasis : JTH 20070501

• The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

  Journal of the American College of Cardiology 20070501

• PROactive in patients with type 2 diabetes and previous myocardial infarction: swinging the sword of Damocles?

  Journal of the American College of Cardiology 20070501

• [Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity].

  Annales pharmaceutiques francaises 20070501

• Ligands of peroxisome proliferator-activated receptor inhibit homocysteine-induced DNA methylation of inducible nitric oxide synthase gene.

  Acta biochimica et biophysica Sinica 20070501

• Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance.

  Heart and vessels 20070501

• Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070501

• Induction of long-term glycemic control in type 2 diabetic patients using pioglitazone and metformin combination.

  The Journal of the Association of Physicians of India 20070501

• Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.

  Current diabetes reviews 20070501

• Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.

  European journal of pharmacology 20070430

• Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats.

  Yonsei medical journal 20070430

• Diabetes drugs tied to fractures in women.

  JAMA 20070418

• Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis.

  World journal of gastroenterology 20070407

• Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone.

  Diabetes research and clinical practice 20070401

• Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

  American journal of physiology. Renal physiology 20070401

• Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.

  The Journal of clinical endocrinology and metabolism 20070401

• Overexpression of GLUT5 in diabetic muscle is reversed by pioglitazone.

  Diabetes care 20070401

• Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-gamma in human proximal renal tubular cells.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070401

• Impacts of long-term treatments with testosterone replacement and pioglitazone on glucose and lipid metabolism in male patients with Werner's syndrome.

  Clinica chimica acta; international journal of clinical chemistry 20070401

• Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats.

  Free radical biology & medicine 20070401

• Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20070401

• Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.

  Metabolism: clinical and experimental 20070401

• Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.

  Metabolism: clinical and experimental 20070401

• Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus.

  International journal of clinical practice 20070401

• Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.

  Journal of neurochemistry 20070401

• Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus.

  Journal of atherosclerosis and thrombosis 20070401

• New oral agents for type 2 diabetes.

  Clinical medicine (London, England) 20070401

• Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes.

  Journal of endocrinological investigation 20070401

• Pioglitazone vs glimepiride and carotid intima-media thickness.

  JAMA 20070328

• Pioglitazone vs glimepiride and carotid intima-media thickness.

  JAMA 20070328

• Pioglitazone in nonalcoholic steatohepatitis.

  The New England journal of medicine 20070308

• Pioglitazone in nonalcoholic steatohepatitis.

  The New England journal of medicine 20070308

• Pioglitazone in nonalcoholic steatohepatitis.

  The New England journal of medicine 20070308

• Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines.

  American journal of physiology. Cell physiology 20070301

• Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.

  Molecular pharmacology 20070301

• Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats.

  Vascular pharmacology 20070301

• Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.

  Journal of neurochemistry 20070301

• Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).

  Stroke 20070301

• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

  Diabetes, obesity & metabolism 20070301

• Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20070301

• Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression.

  Diabetes 20070301

• Pioglitazone trial for NASH: results show promise.

  Gastroenterology 20070301

• [Effects of pioglitazone on the morphology and the expression of connective tissue growth factor of transforming growth factor beta-induced rat hepatic stellate cells in vitro].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20070301

• Bioequivalence study of 30 mg pioglitazone tablets in Thai healthy volunteers.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20070301

• Inter-subject differences in constitutive expression levels of the clock gene in man.

  Diabetes & vascular disease research 20070301

• A lack of synergistic interaction between insulin and pioglitazone on reactivity of rat aorta from chronically high dose insulin-treated diabetic rats.

  General physiology and biophysics 20070301

• [Too positive comment on glitazones].

  Ugeskrift for laeger 20070219

• Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma.

  Vascular pharmacology 20070201

• Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach.

  Molecular pharmacology 20070201

• Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.

  The Journal of clinical endocrinology and metabolism 20070201

• High glucose-boosted inflammatory responses to lipopolysaccharide are suppressed by statin.

  Journal of periodontal research 20070201

• Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.

  Internal medicine journal 20070201

• Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart.

  Prostaglandins & other lipid mediators 20070201

• Pioglitazone induces de novo ceramide synthesis in the rat heart.

  Prostaglandins & other lipid mediators 20070201

• Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.

  Clinical pharmacology and therapeutics 20070201

• Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts.

  Journal of neurosurgery 20070201

• The anti-atherogenic effects of thiazolidinediones.

  Current diabetes reviews 20070201

• Pioglitazone/glimepiride (Duetact) for diabetes.

  The Medical letter on drugs and therapeutics 20070129

• Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.

  Journal of the American College of Cardiology 20070123

• Adjudication of serious heart failure in patients from PROactive.

  Lancet (London, England) 20070120

• Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance.

  Diabetes research and clinical practice 20070101

• A patient with Werner syndrome and adiponectin gene mutation.

  Diabetes research and clinical practice 20070101

• Effects of thiazolidinediones on stroke recovery: a case-matched controlled study.

  Neurochemical research 20070101

• Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes.

  American journal of physiology. Endocrinology and metabolism 20070101

• Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.

  The Journal of clinical endocrinology and metabolism 20070101

• Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1.

  Arteriosclerosis, thrombosis, and vascular biology 20070101

• Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone.

  Laboratory investigation; a journal of technical methods and pathology 20070101

• Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease.

  Cardiology 20070101

• Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice.

  International journal of molecular medicine 20070101

• Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

  Current atherosclerosis reports 20070101

• [Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].

  Der Internist 20070101

• Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment.

  International journal of radiation oncology, biology, physics 20070101

• A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

  PharmacoEconomics 20070101

• Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug.

  Journal of clinical pharmacology 20070101

• Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet.

  Journal of clinical pharmacology 20070101

• The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight.

  Diabetes, obesity & metabolism 20070101

• Pharmacokinetic interactions with thiazolidinediones.

  Clinical pharmacokinetics 20070101

• Effect of pioglitazone treatment on behavioral symptoms in autistic children.

  Journal of neuroinflammation 20070101

• Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.

  Gastroenterology 20070101

• Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications.

  American journal of nephrology 20070101

• Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeys.

  Reproductive toxicology (Elmsford, N.Y.) 20070101

• Interleukin-4 inhibition of interleukin-1-induced expression of matrix metalloproteinase-3 (MMP-3) is independent of lipoxygenase and PPARgamma activation in human gingival fibroblasts.

  BMC molecular biology 20070101

• Pioglitazone as a therapeutic agent in autistic spectrum disorder.

  Medical hypotheses 20070101

• Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats.

  Pharmacology 20070101

• Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus.

  Clinical laboratory 20070101

• Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070101

• Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20070101

• Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.

  Kidney & blood pressure research 20070101

• Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.

  BMC medicine 20070101

• Actos and Avandia in type 2 diabetes. Where do they fit?

  Diabetes self-management 20070101

• [Microinflammation in the pathogenesis of diabetic nephropathy].

  Nihon Jinzo Gakkai shi 20070101

• Sitagliptin: a novel drug for the treatment of type 2 diabetes.

  Cardiology in review 20070101

• A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

  PharmacoEconomics 20070101

• Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20070101

• Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma.

  Internal medicine (Tokyo, Japan) 20070101

• Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.

  Clinical therapeutics 20070101

• Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma.

  Respiratory research 20070101

• Effect of a polyphenol-rich extract from Aloe vera gel on experimentally induced insulin resistance in mice.

  The American journal of Chinese medicine 20070101

• Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.

  Oncology 20070101

• Pioglitazone acutely influences glucose-sensitive insulin secretion in normal and diabetic human islets.

  Biochemical and biophysical research communications 20061222

• Pioglitazone limits cyclosporine nephrotoxicity in rats.

  International immunopharmacology 20061220

• Severe pulmonary metastasis in obese and diabetic mice.

  International journal of cancer 20061215

• Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

  JAMA 20061206

• Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance.

  Diabetes research and clinical practice 20061201

• The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.

  American journal of physiology. Endocrinology and metabolism 20061201

• The relationship between plasma adiponectin concentration and insulin resistance is altered in smokers.

  The Journal of clinical endocrinology and metabolism 20061201

• Pioglitazone increases gallbladder volume in insulin-resistant obese mice.

  The Journal of surgical research 20061201

• Rosiglitazone inhibits mouse liver regeneration.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061201

• Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.

  International journal of oncology 20061201

• Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.

  Clinical endocrinology 20061201

• International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.

  Pharmacological reviews 20061201

• Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes.

  The Journal of pediatrics 20061201

• Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus.

  American heart journal 20061201

• Peroxisome proliferator-activated receptor gamma ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit.

  Journal of cardiovascular pharmacology 20061201

• The pharmacokinetics of pioglitazone in Thai healthy subjects.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20061201

• Effect of pioglitazone on the expression of inflammatory cytokines in attenuating rat cardiomyocyte hypertrophy.

  Methods and findings in experimental and clinical pharmacology 20061201

• Organ protection in the secondary prevention of type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20061201

• Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones.

  The Journal of pharmacy and pharmacology 20061201

• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  The New England journal of medicine 20061130

• Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time.

  The New England journal of medicine 20061130

• High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061107

• The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.

  European journal of pharmacology 20061107

• Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats.

  Life sciences 20061102

• Hepatocyte growth factor secreted by cultured adipocytes promotes tube formation of vascular endothelial cells in vitro.

  International journal of obesity (2005) 20061101

• Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes.

  American journal of physiology. Endocrinology and metabolism 20061101

• Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.

  Molecular pharmacology 20061101

• The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.

  Journal of lipid research 20061101

• Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.

  Metabolism: clinical and experimental 20061101

• Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials.

  Current medical research and opinion 20061101

• [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].

  Nihon rinsho. Japanese journal of clinical medicine 20061101

• Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques.

  Journal of cardiovascular pharmacology 20061101

• [Assessment of left ventricular diastolic function with pioglitazone in type 2 diabetic patients].

  Journal of cardiology 20061101

• Effects of pioglitazone and high-fat diet on ceramide metabolism in rat skeletal muscles.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20061101

• [The practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners; a response from the perspective of general practice].

  Nederlands tijdschrift voor geneeskunde 20061021

• Pioglitazone for type 2 diabetes mellitus.

  The Cochrane database of systematic reviews 20061018

• [New subgroup analysis of the PROactive Study. Risk for recurrent stroke cut in half].

  MMW Fortschritte der Medizin 20061012

• Treatment of obesity with diet/exercise versus pioglitazone has distinct effects on lipoprotein particle size.

  Atherosclerosis 20061001

• Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay.

  Biomedical chromatography : BMC 20061001

• Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone.

  American journal of physiology. Heart and circulatory physiology 20061001

• Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.

  Drug metabolism and disposition: the biological fate of chemicals 20061001

• Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.

  Kidney international 20061001

• Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.

  Pharmacotherapy 20061001

• The effect of pioglitazone on the liver: role of adiponectin.

  Diabetes care 20061001

• A patient with extreme insulin resistance syndrome treated with pioglitazone.

  Diabetes care 20061001

• Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone.

  Diabetes 20061001

• Lipin expression is attenuated in adipose tissue of insulin-resistant human subjects and increases with peroxisome proliferator-activated receptor gamma activation.

  Diabetes 20061001

• [PPAR gamma ligand pioglitazone as a therapeutic strategy in nonalcoholic steatohepatitis (NASH)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20061001

• Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes.

  Annals of the New York Academy of Sciences 20061001

• Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.

  Journal of atherosclerosis and thrombosis 20061001

• [Werner's syndrome].

  Nihon rinsho. Japanese journal of clinical medicine 20060928

• Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.

  American journal of physiology. Heart and circulatory physiology 20060901

• Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus.

  American journal of physiology. Renal physiology 20060901

• Peroxisome proliferator-activated receptors increase human sebum production.

  The Journal of investigative dermatology 20060901

• Fibroblasts isolated from human pterygia exhibit altered lipid metabolism characteristics.

  Experimental eye research 20060901

• Pioglitazone induces apoptosis of macrophages in human adipose tissue.

  Journal of lipid research 20060901

• Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers.

  The Journal of clinical endocrinology and metabolism 20060901

• Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice.

  Diabetologia 20060901

• Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.

  Journal of hypertension 20060901

• PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.

  Clinical endocrinology 20060901

• A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.

  Digestive diseases and sciences 20060901

• Effects of treatment for diabetes mellitus on circulating vascular progenitor cells.

  Journal of pharmacological sciences 20060901

• [Preventive effects of pioglitazone on rat fatty liver induced by a high fat diet].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20060901

• Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy.

  Wiener klinische Wochenschrift 20060901

• [Expression of PPAR-gamma in human hilar bile duct carcinoma cell line QBC939 and the effects of PPAR-Y activated by its ligand on the growth of QBC939].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20060901

• [Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20060901

• [Bioequivalence assessment of pioglitazone hydrochloride oral preparation by limited sampling strategy].

  Yao xue xue bao = Acta pharmaceutica Sinica 20060901

• Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat.

  Circulation 20060829

• [Glitazone treatment of type 2 diabetes mellitus].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20060810

• Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice.

  Brain research 20060802

• Pioglitazone decreased CD40/CD40L expression on human umbilical vein endothelial cells induced by oxidized low-density lipoprotein.

  Clinica chimica acta; international journal of clinical chemistry 20060801

• A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.

  The Journal of pharmacology and experimental therapeutics 20060801

• Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.

  Fertility and sterility 20060801

• Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20060801

• Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells.

  International journal of oncology 20060801

• Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin.

  Metabolism: clinical and experimental 20060801

• Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.

  Journal of Zhejiang University. Science. B 20060801

• Pioglitazone reduces endothelial microparticles in the metabolic syndrome.

  Arteriosclerosis, thrombosis, and vascular biology 20060801

• Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat.

  Diabetes 20060801

• Case report of Klinefelter's syndrome with severe diabetes, dyslipidemia, and stroke: The effect of pioglitazone and other anti-inflammatory agents on interleukin-6 and -8, tumor necrosis factor-alpha, and C-reactive protein.

  Diabetes care 20060801

• Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

  Journal of clinical pharmacy and therapeutics 20060801

• Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.

  Journal of internal medicine 20060801

• Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes.

  The Lancet. Oncology 20060801

• Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.

  Clinical pharmacology and therapeutics 20060801

• Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry.

  Chemical research in toxicology 20060801

• Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.

  Anti-cancer drugs 20060801

• Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis.

  Clinical therapeutics 20060801

• [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].

  Lakartidningen 20060801

• Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.

  Molecular diversity 20060801

• Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats.

  Gut 20060701

• Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus.

  American journal of physiology. Heart and circulatory physiology 20060701

• Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.

  European journal of clinical pharmacology 20060701

• The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.

  British journal of pharmacology 20060701

• TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.

  European heart journal 20060701

• The role of PPARs in the microvascular dysfunction in diabetes.

  Vascular pharmacology 20060701

• Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.

  Diabetes care 20060701

• Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.

  The Journal of allergy and clinical immunology 20060701

• Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes.

  Clinical endocrinology 20060701

• Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.

  Basic & clinical pharmacology & toxicology 20060701

• 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.

  Molecular cancer therapeutics 20060701

• Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.

  Expert review of cardiovascular therapy 20060701

• Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome.

  WMJ : official publication of the State Medical Society of Wisconsin 20060701

• [Resveratrol inhibits expression of EMMPRIN from macrophages].

  Yao xue xue bao = Acta pharmaceutica Sinica 20060701

• Pioglitazone prevents acute and chronic cardiac allograft rejection.

  Circulation 20060606

• A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

  Journal of pharmacokinetics and pharmacodynamics 20060601

• Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.

  Journal of the American Society of Nephrology : JASN 20060601

• Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus.

  Endocrine journal 20060601

• Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.

  Diabetes 20060601

• Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes.

  Diabetes care 20060601

• [PPAR and NASH].

  Nihon rinsho. Japanese journal of clinical medicine 20060601

• [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].

  Nihon rinsho. Japanese journal of clinical medicine 20060601

• Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060601

• Thiazolidinedione derivatives in type 2 diabetes mellitus.

  The Netherlands journal of medicine 20060601

• Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.

  Current medical research and opinion 20060601

• The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

  The American journal of geriatric pharmacotherapy 20060601

• Impaired insulin-regulated membrane aminopeptidase translocation to the plasma membrane in adipocytes of Otsuka Long Evans Tokushima Fatty rats.

  Nagoya journal of medical science 20060601

• Reimbursement decision-making and prescription patterns of glitazones in treatment of type 2 diabetes mellitus patients in Denmark.

  Health care analysis : HCA : journal of health philosophy and policy 20060601

• Adverse events related to muraglitazar use in diabetes.

  JAMA 20060503

• Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells.

  Molecular pharmacology 20060501

• The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin.

  Diabetologia 20060501

• Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis.

  Kidney international 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.

  Diabetes care 20060501

• Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

  Diabetes care 20060501

• Suspected suppression of the INR by thiazolidinediones: interaction between warfarin and TZDs.

  The Annals of pharmacotherapy 20060501

• Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians.

  Diabetic medicine : a journal of the British Diabetic Association 20060501

• [The place of Glitazones in the treatment of diabetes: after the PROactive study].

  Ugeskrift for laeger 20060501

• Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.

  Diabetes & vascular disease research 20060501

• Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

  Clinical therapeutics 20060501

• [The role of peroxisome proliferator-activated receptor gamma in proliferation of cardiac non myocytes].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20060501

• [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].

  Nederlands tijdschrift voor geneeskunde 20060422

• [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].

  Nederlands tijdschrift voor geneeskunde 20060422

• Treatment of nonalcoholic fatty liver disease.

  World journal of gastroenterology 20060414

• Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060411

• Lipid metabolism.

  Current opinion in lipidology 20060401

• Pioglitazone treatment improves nitrosative stress in type 2 diabetes.

  Diabetes care 20060401

• Peroxisome proliferator-activated receptor gamma ligands stimulate myeloid differentiation and lipogenensis in human leukemia NB4 cells.

  Development, growth & differentiation 20060401

• Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.

  American journal of hypertension 20060401

• Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.

  Biological chemistry 20060401

• Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.

  Current medical research and opinion 20060401

• [41th Congress of EASD (European Association for The Study of Diabetes) 10 to 15 September 2005, Athens, Greece].

  La Revue de medecine interne 20060401

• Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.

  The Journal of biological chemistry 20060331

• PROactive study.

  Lancet (London, England) 20060325

• Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.

  Proceedings of the National Academy of Sciences of the United States of America 20060307

• Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy.

  American journal of physiology. Renal physiology 20060301

• The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.

  Diabetologia 20060301

• Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.

  European journal of clinical pharmacology 20060301

• Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.

  Diabetes, obesity & metabolism 20060301

• Tissue-specific regulation of malonyl-CoA decarboxylase activity in OLETF rats.

  Diabetes, obesity & metabolism 20060301

• Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20060301

• Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study.

  Diabetic medicine : a journal of the British Diabetic Association 20060301

• Type 2 diabetes, psoriasis and thiazolidinediones.

  International journal of clinical practice 20060301

• Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.

  Expert opinion on pharmacotherapy 20060301

• Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.

  Diabetes care 20060301

• Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma.

  Biological & pharmaceutical bulletin 20060301

• Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.

  Journal of managed care pharmacy : JMCP 20060301

• Pioglitazone, a synthetic ligand for PPARgamma, induces apoptosis in RB-deficient human colorectal cancer cells.

  Apoptosis : an international journal on programmed cell death 20060301

• Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human.

  Molecular and cellular biochemistry 20060301

• [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].

  Kardiologia polska 20060301

• Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels.

  Journal of endocrinological investigation 20060301

• [Positioning of PROactive and its clinical application in Japan--a new direction in diabetes care discussed by diabetology and circulatory disease specialists: discussion].

  Nihon rinsho. Japanese journal of clinical medicine 20060301

• [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].

  Nederlands tijdschrift voor geneeskunde 20060218

• Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.

  Circulation 20060214

• Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1.

  Endocrinology 20060201

• Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.

  Diabetes 20060201

• The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPARgamma agonist restores normal cell signaling and differentiation.

  The Journal of endocrinology 20060201

• Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.

  Pharmacotherapy 20060201

• The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.

  Current diabetes reports 20060201

• Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060201

• Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.

  Endocrine 20060201

• Pioglitazone/metformin (Actoplus met).

  The Medical letter on drugs and therapeutics 20060130

• Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin.

  Biochemical and biophysical research communications 20060127

• Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion.

  European journal of pharmacology 20060113

• [Are pioglitazone and fenofibrate effective for the prevention of cardiovascular disease in type 2 diabetes?].

  Revue medicale suisse 20060111

• PROactive study.

  Lancet (London, England) 20060107

• PROactive study.

  Lancet (London, England) 20060107

• PROactive study.

  Lancet (London, England) 20060107

• PROactive study.

  Lancet (London, England) 20060107

• PROactive study.

  Lancet (London, England) 20060107

• Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression.

  American journal of physiology. Endocrinology and metabolism 20060101

• Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.

  Arteriosclerosis, thrombosis, and vascular biology 20060101

• Commentary: the PROactive study--the glass is half full.

  The Journal of clinical endocrinology and metabolism 20060101

• Pioglitazone increases non-esterified fatty acid clearance in upper body obesity.

  Diabetologia 20060101

• Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.

  Metabolism: clinical and experimental 20060101

• Effects of pioglitazone in familial combined hyperlipidaemia.

  Journal of internal medicine 20060101

• Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20060101

• A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.

  Diabetes care 20060101

• Diabetes treatments have differential effects on nontraditional cardiovascular risk factors.

  Journal of diabetes and its complications 20060101

• Effect of rifampicin on the pharmacokinetics of pioglitazone.

  British journal of clinical pharmacology 20060101

• Pioglitazone: a review of its use in type 2 diabetes mellitus.

  Drugs 20060101

• Regulation of lipoprotein lipase expression by effect of hawthorn flavonoids on peroxisome proliferator response element pathway.

  Journal of pharmacological sciences 20060101

• A meta-analysis of the effect of thiazolidinediones on blood pressure.

  Journal of clinical hypertension (Greenwich, Conn.) 20060101

• Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats.

  Gynecologic and obstetric investigation 20060101

• Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.

  Diabetes/metabolism research and reviews 20060101

• Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells.

  The international journal of biochemistry & cell biology 20060101

• Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening.

  International journal of toxicology 20060101

• Interleukin-6 and oxidative stress in plasma of alloxan-induced diabetic rabbits after pioglitazone treatment.

  Immunopharmacology and immunotoxicology 20060101

• Diabetic macular edema associated with glitazone use.

  Retina (Philadelphia, Pa.) 20060101

• The effects of thiazolidinediones on blood pressure levels - a systematic review.

  Blood pressure 20060101

• Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20060101

• Metformin and pioglitazone: Effectively treating insulin resistance.

  Current medical research and opinion 20060101

• A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.

  Current medical research and opinion 20060101

• Pioglitazone/metformin.

  Drugs 20060101

• New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).

  Acta medica Indonesiana 20060101

• Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.

  The Journal of international medical research 20060101

• [Current options of insulin resistence correction in patients with metabolic syndrome].

  Terapevticheskii arkhiv 20060101

• [Metabolic and hemodynamic effects of pioglitazone in obese patients with type 2 diabetes].

  Klinicheskaia meditsina 20060101

• Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma.

  Molecular pharmacology 20051201

• Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue.

  Endocrinology 20051201

• Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.

  Diabetologia 20051201

• Effect of gemfibrozil on the pharmacokinetics of pioglitazone.

  European journal of clinical pharmacology 20051201

• Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.

  Diabetes 20051201

• Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

  Journal of cardiovascular pharmacology 20051201

• Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK.

  Journal of cardiovascular pharmacology 20051201

• FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.

  Journal of pharmacological sciences 20051201

• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al.

  Diabetes care 20051201

• Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension.

  American journal of hypertension 20051201

• A new therapeutic approach in patients with advanced sarcoma.

  International journal of clinical oncology 20051201

• Protective effect of pioglitazone against endotoxin-induced liver injury through prevention of Kupffer cell sensitization.

  Alcoholism, clinical and experimental research 20051201

• Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20051201

• [The benefit of pioglitazone in patients with diabetes mellitus type 2 and cardiovascular complications].

  Vnitrni lekarstvi 20051201

• [Pioglitazone. Review of its metabolic and systemic effects].

  Revista clinica espanola 20051201

• New drugs.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20051115

• [PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20051103

• PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose.

  American journal of physiology. Renal physiology 20051101

• Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production.

  The Journal of clinical endocrinology and metabolism 20051101

• Rating the severity of the medical consequences of drug-induced liver injury.

  Regulatory toxicology and pharmacology : RTP 20051101

• Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.

  Diabetes research and clinical practice 20051101

• PROactive Study: (r)evolution in the therapy of diabetes?

  Diabetic medicine : a journal of the British Diabetic Association 20051101

• Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.

  Circulation 20051101

• Prevention of restenosis by systemic drug therapy: back to the future?

  Circulation 20051101

• [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].

  Revue medicale de Liege 20051101

• Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.

  Clinical and experimental pharmacology & physiology 20051101

• Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.

  Hypertension research : official journal of the Japanese Society of Hypertension 20051101

• Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis.

  World journal of gastroenterology 20051028

• Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients.

  Journal of immunology (Baltimore, Md. : 1950) 20051015

• [New studies, new strategies, new guidelines: so that diabetic patients will live longer].

  MMW Fortschritte der Medizin 20051013

• [How does the PROactive Study change therapy of diabetes?].

  MMW Fortschritte der Medizin 20051013

• How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

  BMJ (Clinical research ed.) 20051008

• The PROactive study: some answers, many questions.

  Lancet (London, England) 20051008

• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  Lancet (London, England) 20051008

• Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening.

  Pharmacological research 20051001

• Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.

  Diabetes research and clinical practice 20051001

• Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.

  The Journal of clinical endocrinology and metabolism 20051001

• Effect of pioglitazone on L-NAME induced hypertension in diabetic rats.

  Vascular pharmacology 20051001

• Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes.

  Journal of clinical pharmacology 20051001

• Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.

  Pharmacotherapy 20051001

• Rational drug design and PPAR agonists.

  Current diabetes reports 20051001

• PPARgamma agonists: a new strategy for antithrombotic therapy.

  Journal of thrombosis and haemostasis : JTH 20051001

• Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance.

  Journal of thrombosis and haemostasis : JTH 20051001

• [Role of peroxisome proliferators activated receptor gamma in mediating proliferation of rat vascular smooth muscle cells induced by advanced glycation end products].

  Zhonghua xin xue guan bing za zhi 20051001

• Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

  Clinical therapeutics 20051001

• [World news in age-related diabetes: blood sugar lowering can improve prognosis].

  MMW Fortschritte der Medizin 20050922

• Leukopenia and thrombocytopenia caused by thiazolidinediones.

  Annals of internal medicine 20050920

• Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.

  European journal of pharmacology 20050905

• Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.

  Biochemical and biophysical research communications 20050902

• Cardioprotective effects of peroxisome proliferator activated receptor gamma activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor kappaB blockade.

  Heart (British Cardiac Society) 20050901

• Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione.

  European journal of medicinal chemistry 20050901

• PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.

  Arteriosclerosis, thrombosis, and vascular biology 20050901

• Pioglitazone prevents reactive hypoglycemia in impaired glucose tolerance.

  Diabetes research and clinical practice 20050901

• The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

  Molecular cancer therapeutics 20050901

• The pluses of pioglitazone.

  Diabetes forecast 20050901

• Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.

  Clinical therapeutics 20050901

• The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050824

• Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation.

  Biochemical and biophysical research communications 20050819

• Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20050801

• Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis.

  Hypertension (Dallas, Tex. : 1979) 20050801

• Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.

  Diabetic medicine : a journal of the British Diabetic Association 20050801

• Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20050801

• Pioglitazone initiation and subsequent hospitalization for congestive heart failure.

  Diabetic medicine : a journal of the British Diabetic Association 20050801

• Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.

  Diabetic medicine : a journal of the British Diabetic Association 20050801

• Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit.

  Atherosclerosis 20050801

• Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone.

  Diabetes 20050801

• Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone.

  Molecular human reproduction 20050801

• Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.

  Geriatrics 20050801

• Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20050801

• Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20050801

• Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin.

  Internal medicine (Tokyo, Japan) 20050801

• Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus.

  Journal of the Indian Medical Association 20050801

• Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.

  European journal of pharmacology 20050711

• Differential regulation and properties of angiopoietin-like proteins 3 and 4.

  Journal of lipid research 20050701

• A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy.

  Kidney international 20050701

• A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.

  Diabetes research and clinical practice 20050701

• Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20050701

• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  Diabetes care 20050701

• The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.

  The European journal of neuroscience 20050701

• Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.

  American journal of hypertension 20050701

• [In vitro study of the effects of pioglitazone on endothelial cell functions of human umbilical vein and the mechanisms involved].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20050701

• [The effect of pioglitazone on apoptotic cardiomyocytes for ischemia reperfusion].

  Zhonghua xin xue guan bing za zhi 20050701

• Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.

  Journal of the American College of Cardiology 20050621

• Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20050601

• PPAR-gamma modulates allergic inflammation through up-regulation of PTEN.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050601

• Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.

  Brain : a journal of neurology 20050601

• Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

  Diabetologia 20050601

• Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.

  Acta pharmacologica Sinica 20050601

• Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.

  Endocrine-related cancer 20050601

• Alteration in endothelial function and modulation by treatment with pioglitazone in rabbit renal artery from short-term hypercholesterolemia.

  Vascular pharmacology 20050601

• Relationship between plasma hANP level and pretibial edema by pioglitazone treatment.

  Endocrine journal 20050601

• Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)gamma.

  Cell biology international 20050601

• Thiazolidinediones in type 2 diabetes--have they lived up to expectations?

  Journal of the Indian Medical Association 20050601

• Insulin resistance index as a predictor for pioglitazone treatment in type 2 diabetes.

  Osaka city medical journal 20050601

• Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.

  Circulation 20050517

• Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

  The Journal of clinical investigation 20050502

• Effectiveness and side effects of thiazolidinediones for type 2 diabetes.

  The Medical journal of Australia 20050502

• Effectiveness and side effects of thiazolidinediones for type 2 diabetes.

  The Medical journal of Australia 20050502

• Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.

  American journal of physiology. Endocrinology and metabolism 20050501

• Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.

  Acta pharmacologica Sinica 20050501

• Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo.

  Diabetes 20050501

• Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes.

  Diabetes care 20050501

• Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide.

  Diabetes research and clinical practice 20050501

• Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E.

  The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20050501

• Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells.

  Thrombosis and haemostasis 20050501

• The Clinical Significance of PPAR Gamma Agonism.

  Current molecular medicine 20050501

• Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.

  Clinical pharmacology and therapeutics 20050501

• Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

  Clinical therapeutics 20050501

• [Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].

  MMW Fortschritte der Medizin 20050428

• Identification of adipocyte adhesion molecule (ACAM), a novel CTX gene family, implicated in adipocyte maturation and development of obesity.

  The Biochemical journal 20050415

• The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis.

  The Journal of biological chemistry 20050408

• Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.

  Biochemical and biophysical research communications 20050408

• Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment.

  The Journal of clinical endocrinology and metabolism 20050401

• The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines.

  Cell cycle (Georgetown, Tex.) 20050401

• Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats.

  Cardiovascular research 20050401

• A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.

  Diabetic medicine : a journal of the British Diabetic Association 20050401

• Hypoadiponectinemia is caused by chronic blockade of nitric oxide synthesis in rats.

  Metabolism: clinical and experimental 20050401

• Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones.

  Metabolism: clinical and experimental 20050401

• Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6).

  International journal of dermatology 20050401

• [Long-term treatment of diabetes mellitus in myotonic dystrophy with pioglitazone].

  Rinsho shinkeigaku = Clinical neurology 20050401

• Pioglitazone treatment in Cushing's disease.

  Journal of endocrinological investigation 20050401

• PPAR-gamma ligands up-regulate basic fibroblast growth factor-induced VEGF release through amplifying SAPK/JNK activation in osteoblasts.

  Biochemical and biophysical research communications 20050304

• Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice.

  American journal of physiology. Endocrinology and metabolism 20050301

• Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease.

  The Journal of clinical endocrinology and metabolism 20050301

• Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.

  The Journal of clinical endocrinology and metabolism 20050301

• Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.

  The Journal of clinical endocrinology and metabolism 20050301

• Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

  Journal of the American Society of Nephrology : JASN 20050301

• Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050301

• Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.

  Diabetes, obesity & metabolism 20050301

• Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand.

  Experimental eye research 20050301

• The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation.

  Cardiovascular research 20050301

• Thiazolidinedione (pioglitazone) blocks P. gingivalis- and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes.

  Journal of dental research 20050301

• Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults.

  British journal of haematology 20050301

• Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism.

  Diabetes 20050301

• Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.

  Diabetes care 20050301

• Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms.

  Inflammatory bowel diseases 20050301

• Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.

  Diabetologia 20050301

• Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.

  Urology 20050301

• PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer.

  Neoplasia (New York, N.Y.) 20050301

• Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20050301

• Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20050301

• A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia.

  Stroke 20050201

• Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis.

  Experimental neurology 20050201

• Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity.

  Clinica chimica acta; international journal of clinical chemistry 20050201

• The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.

  British journal of pharmacology 20050201

• Regarding the use of HOMA to aid drug selection.

  Diabetic medicine : a journal of the British Diabetic Association 20050201

• Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.

  Diabetes care 20050201

• Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs.

  Arthritis and rheumatism 20050201

• Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism.

  Atherosclerosis 20050201

• Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance.

  Journal of molecular and cellular cardiology 20050201

• [Pexoxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20050201

• Thiazolidinediones for treatment of polycystic ovary syndrome.

  Pharmacotherapy 20050201

• [Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].

  Nihon rinsho. Japanese journal of clinical medicine 20050201

• [Effect of pioglitazone, one of TZDs, on IGT-patients].

  Nihon rinsho. Japanese journal of clinical medicine 20050201

• Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.

  International journal of clinical practice 20050201

• [Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20050201

• Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration.

  European journal of pharmacology 20050131

• Thiazolidinediones.

  The New England journal of medicine 20050113

• [Glucose-independent impact of the glitazones on the cardiovascular outcome].

  MMW Fortschritte der Medizin 20050113

• Mest/Peg1 imprinted gene enlarges adipocytes and is a marker of adipocyte size.

  American journal of physiology. Endocrinology and metabolism 20050101

• Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.

  Diabetes/metabolism research and reviews 20050101

• Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries.

  Pharmacology 20050101

• Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.

  Rheumatology (Oxford, England) 20050101

• Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.

  Metabolism: clinical and experimental 20050101

• Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment.

  Metabolism: clinical and experimental 20050101

• Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia.

  Neuroscience 20050101

• Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects.

  Diabetologia 20050101

• Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.

  The Journal of endocrinology 20050101

• Pioglitazone: a promising therapy for psoriasis.

  The British journal of dermatology 20050101

• Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20050101

• Insulin sensitizer affects lipids.

  Health news (Waltham, Mass.) 20050101

• [The impact of pioglitazone on plasma homocysteine high-fat diet-induced insulin resistance in rats].

  Zhonghua nei ke za zhi 20050101

• Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials.

  Current medical research and opinion 20050101

• Modification of oxidative stress by pioglitazone in the heart of alloxan-induced diabetic rabbits.

  Journal of biomedical science 20050101

• Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.

  Journal of atherosclerosis and thrombosis 20050101

• Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.

  Cardiology 20050101

• Estimation of pioglitazone hydrochloride and metformin hydrochloride in tablets by derivative spectrophotometry and liquid chromatographic methods.

  Journal of AOAC International 20050101

• [Type 2 diabetic as cardiovascular risk patient].

  Krankenpflege Journal 20050101

• Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

  Microcirculation (New York, N.Y. : 1994) 20050101

• Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties.

  Inflammopharmacology 20050101

• PROactive study shows reduced heart attacks and strokes in type 2 diabetics on pioglitazone HCI (Actos) therapy.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20050101

• The metabolic basis of atherogenic dyslipidemia.

  Clinical cornerstone 20050101

• A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.

  Analytical biochemistry 20041215

• Pioglitazone-induced heart failure despite normal left ventricular function.

  The American journal of medicine 20041215

• Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.

  World journal of gastroenterology 20041201

• Anoxia-reoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPAR-gamma ligand pioglitazone.

  Journal of cardiovascular pharmacology 20041201

• Pioglitazone treatment of insulin resistance in a patient with Werner's syndrome.

  Diabetes care 20041201

• Antidiabetic and adipogenic properties in a newly synthesized thiazolidine derivative, FPFS-410.

  Metabolism: clinical and experimental 20041201

• Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20041201

• Pioglitazone in the management of diabetes mellitus after transplantation.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20041201

• Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

  The Journal of clinical endocrinology and metabolism 20041201

• Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma.

  Archives of dermatology 20041201

• Evaluation of adipose tissue distribution in obese fa/fa Zucker rats by in vivo MR imaging: effects of peroxisome proliferator-activated receptor agonists.

  Magma (New York, N.Y.) 20041201

• Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20041201

• A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20041201

• Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.

  Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20041201

• Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.

  Cancer 20041115

• Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.

  The Medical journal of Australia 20041115

• Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression.

  The Journal of biological chemistry 20041112

• Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.

  Biochemical and biophysical research communications 20041105

• Peroxisome proliferator-activated receptors ligands, oxidative stress, and cardiac fibroblast extracellular matrix turnover.

  Hypertension (Dallas, Tex. : 1979) 20041101

• Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone.

  Hypertension (Dallas, Tex. : 1979) 20041101

• Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.

  Gut 20041101

• Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet.

  Diabetes 20041101

• Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma.

  Anti-cancer drugs 20041101

• Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice.

  Metabolism: clinical and experimental 20041101

• Photo-affinity labeling strategies in identifying the protein ligands of bioactive small molecules: examples of targeted synthesis of drug analog photoprobes.

  Combinatorial chemistry & high throughput screening 20041101

• Structural characterization of impurities in pioglitazone.

  Die Pharmazie 20041101

• Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats.

  Canadian journal of physiology and pharmacology 20041101

• A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

  Archives of internal medicine 20041025

• Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation.

  Biochemical and biophysical research communications 20041022

• Liver toxicity and pioglitazone: data are missing.

  BMJ (Clinical research ed.) 20041016

• Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients.

  Metabolism: clinical and experimental 20041001

• Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products.

  Diabetes 20041001

• Dysadipocytokinemia in werner syndrome and its recovery by treatment with pioglitazone.

  Diabetes care 20041001

• Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta.

  The Journal of clinical endocrinology and metabolism 20041001

• Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.

  International journal of clinical practice 20041001

• Generic, highly selective and robust capillary electrophoresis method for separation of a racemic mixture of glitazone compounds.

  Journal of chromatography. A 20040917

• Effect of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11.

  European journal of pharmacology 20040913

• Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.

  Circulation research 20040903

• The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells.

  American journal of physiology. Renal physiology 20040901

• Second-generation thiazolidinediones and hepatotoxicity.

  The Annals of pharmacotherapy 20040901

• A case of secondary diabetes mellitus with acromegaly improved by pioglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20040901

• Metabolic improvement and abdominal fat redistribution in Werner syndrome by pioglitazone.

  Journal of the American Geriatrics Society 20040901

• Expression of uncoupling protein-3 mRNA in rat skeletal muscle is acutely stimulated by thiazolidinediones: an exercise-like effect?

  Diabetologia 20040901

• Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

  The Journal of clinical endocrinology and metabolism 20040901

• In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets.

  Arzneimittel-Forschung 20040901

• Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.

  International journal of clinical practice 20040901

• Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.

  Clinical therapeutics 20040901

• Characterization of endothelium-dependent relaxation and modulation by treatment with pioglitazone in the hypercholesterolemic rabbit renal artery.

  European journal of pharmacology 20040830

• Fatal liver failure associated with pioglitazone.

  BMJ (Clinical research ed.) 20040821

• Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance.

  The Journal of biological chemistry 20040806

• Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage.

  Biochimica et biophysica acta 20040804

• Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20040801

• Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

  Diabetes care 20040801

• Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.

  The Journal of clinical endocrinology and metabolism 20040801

• Night-time restricted feeding normalises clock genes and Pai-1 gene expression in the db/db mouse liver.

  Diabetologia 20040801

• Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha.

  Alcoholism, clinical and experimental research 20040801

• [2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].

  MMW Fortschritte der Medizin 20040722

• [Warning signals insulin resistance. Insulin resistance causes not only diabetes].

  MMW Fortschritte der Medizin 20040722

• Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes.

  Clinical chemistry 20040701

• Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.

  Diabetes, obesity & metabolism 20040701

• Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity.

  Free radical biology & medicine 20040701

• The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.

  Diabetes care 20040701

• The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo.

  Diabetes care 20040701

• Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications.

  Clinical chemistry 20040701

• Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats.

  Chinese medical journal 20040701

• Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.

  British journal of pharmacology 20040701

• [Ameliorations of pioglitazone on insulin resistance in spontaneous IGT-OLETF rats].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040701

• Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.

  European journal of pharmacology 20040628

• Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20040601

• An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

  Diabetic medicine : a journal of the British Diabetic Association 20040601

• Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.

  Diabetes 20040601

• Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.

  The American journal of cardiology 20040601

• Peroxisome proliferator-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis associated with inhibition of self-sensitive T cells.

  Journal of cardiovascular pharmacology 20040601

• Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients.

  The Journal of endocrinology 20040601

• Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats.

  Methods and findings in experimental and clinical pharmacology 20040601

• Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.

  The Journal of the Association of Physicians of India 20040601

• MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.

  Biochemical and biophysical research communications 20040528

• Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040515

• Modulation of PPARalpha expression and inflammatory interleukin-6 production by chronic glucose increases monocyte/endothelial adhesion.

  Arteriosclerosis, thrombosis, and vascular biology 20040501

• Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients.

  Diabetes, obesity & metabolism 20040501

• Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses.

  Kidney international 20040501

• Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.

  Current medical research and opinion 20040501

• Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.

  Clinical therapeutics 20040501

• Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

  Clinical therapeutics 20040501

• Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury.

  Drugs of today (Barcelona, Spain : 1998) 20040501

• Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes.

  Diabetes & vascular disease research 20040501

• Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione.

  Biochemical and biophysical research communications 20040423

• Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.

  Endocrinology 20040401

• Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats.

  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 20040401

• Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20040401

• Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.

  Thrombosis and haemostasis 20040401

• Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.

  Metabolism: clinical and experimental 20040401

• Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?

  Diabetes 20040401

• Effects of PPARg agonist pioglitazone on rat hepatic fibrosis.

  World journal of gastroenterology 20040401

• Thiazolidinedione-associated congestive heart failure and pulmonary edema.

  Mayo Clinic proceedings 20040401

• Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia.

  Leukemia research 20040401

• [Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data].

  Annales d'endocrinologie 20040401

• Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner.

  Prostaglandins & other lipid mediators 20040401

• [Long-term HbA1c stable. Insulin sensitizer keeps diabetes in check].

  MMW Fortschritte der Medizin 20040325

• [Preventive effects of pioglitazone on diabetes and relevant mechanisms, experimental study on non-obese diabetic mice].

  Zhonghua yi xue za zhi 20040302

• Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients.

  Journal of leukocyte biology 20040301

• PPARgamma ligands attenuate mesangial contractile dysfunction in high glucose.

  Kidney international 20040301

• Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.

  Drug metabolism and disposition: the biological fate of chemicals 20040301

• Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met.

  Gastroenterology 20040301

• Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome.

  Human reproduction (Oxford, England) 20040301

• Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

  The Journal of clinical endocrinology and metabolism 20040301

• Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes.

  Metabolism: clinical and experimental 20040301

• Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.

  Harvard heart letter : from Harvard Medical School 20040301

• Reversed-phase HPLC methods for purity test and assay of pioglitazone hydrochloride in tablets.

  Die Pharmazie 20040301

• Tumor necrosis factor-alpha-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome proliferator-activated receptor-gamma ligand pioglitazone.

  Journal of cardiovascular pharmacology and therapeutics 20040301

• Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

  Clinical therapeutics 20040301

• Pioglitazone reduces blood pressure in non-dipping diabetic patients.

  Minerva endocrinologica 20040301

• Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.

  Biochemical and biophysical research communications 20040227

• Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.

  The American journal of medicine 20040215

• Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo.

  Biochemical and biophysical research communications 20040206

• Identification of a novel mitochondrial protein ('mitoNEET') cross-linked specifically by a thiazolidinedione photoprobe.

  American journal of physiology. Endocrinology and metabolism 20040201

• Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.

  Diabetes research and clinical practice 20040201

• Comparison of pioglitazone and metformin efficacy using homeostasis model assessment.

  Diabetic medicine : a journal of the British Diabetic Association 20040201

• Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20040201

• Long-term glycaemic control with pioglitazone in patients with type 2 diabetes.

  International journal of clinical practice 20040201

• Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20040201

• [Peroxisome poliferator-activated receptors and their modulators].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040201

• Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes.

  American journal of physiology. Endocrinology and metabolism 20040101

• Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity.

  Hypertension (Dallas, Tex. : 1979) 20040101

• Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.

  British journal of pharmacology 20040101

• Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.

  British journal of pharmacology 20040101

• The effect of nitric oxide synthase inhibitor on improved insulin action by pioglitazone in high-fructose-fed rats.

  Metabolism: clinical and experimental 20040101

• Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

  Journal of neurochemistry 20040101

• Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells.

  Diabetes 20040101

• Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.

  Diabetes care 20040101

• One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

  Diabetes care 20040101

• Promotion of colon tumors in C57BL/6J-APC(min)/+ mice by thiazolidinedione PPARgamma agonists and a structurally unrelated PPARgamma agonist.

  Toxicologic pathology 20040101

• Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

  The Journal of clinical endocrinology and metabolism 20040101

• A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

  Hepatology (Baltimore, Md.) 20040101

• Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes.

  The Journal of investigative dermatology 20040101

• Simultaneous high-performance liquid chromatographic determination of pioglitazone and metformin in pharmaceutical-dosage form.

  Journal of chromatographic science 20040101

• [Association of serum sex hormone-binding globulin with type 2 diabetes].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20040101

• Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.

  Current medical research and opinion 20040101

• Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.

  Drugs & aging 20040101

• Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

  PharmacoEconomics 20040101

• Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells.

  BioFactors (Oxford, England) 20040101

• Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.

  Journal of gastroenterology 20040101

• [Pioglitazone-induced acute severe hepatitis].

  Gastroenterologie clinique et biologique 20040101

• Substitution of pioglitazone for troglitazone in patients with type 2 diabetes.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20040101

• Effects of pioglitazone versus rosiglitazone on lipoprotein subclasses.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20040101

• The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest.

  Anticancer research 20040101

• Effects of PPARgamma ligands and C/EBPbeta enhancer on expression of extracellular-superoxide dismutase.

  Redox report : communications in free radical research 20040101

• Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats.

  BMC pharmacology 20040101

• Hypoxia-reoxygenation enhances interleukin-8 production from U937 human monocytic cells.

  Redox report : communications in free radical research 20040101

• Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits.

  Life sciences 20031219

• [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].

  MMW Fortschritte der Medizin 20031218

• Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-A(y) mice.

  Bioorganic & medicinal chemistry letters 20031215

• Australian government tries to stop independent advice on diabetes drugs.

  BMJ (Clinical research ed.) 20031213

• [Peroxisome proliferation-activated receptor-gamma ligands ameliorate autoimmune myocarditis associated with inhibition of T cell immunity].

  Zhonghua yi xue za zhi 20031210

• Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation.

  Arteriosclerosis, thrombosis, and vascular biology 20031201

• Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma.

  Oral oncology 20031201

• Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.

  Current opinion in lipidology 20031201

• Novel PPARgamma-dependent and independent effects for thiazolidinediones.

  Current opinion in lipidology 20031201

• The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages.

  Atherosclerosis 20031201

• Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone.

  The Journal of clinical endocrinology and metabolism 20031201

• Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model.

  Laboratory investigation; a journal of technical methods and pathology 20031201

• [The use of oral antidiabetic drugs in the treatment of polycystic ovary syndrome].

  Zentralblatt fur Gynakologie 20031201

• Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors.

  Cancer 20031115

• Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity.

  Diabetes care 20031101

• Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand.

  Cancer science 20031101

• Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.

  Journal of neuro-oncology 20031101

• Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.

  Digestive diseases and sciences 20031101

• Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.

  The Journal of the Association of Physicians of India 20031101

• Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20031029

• Pioglitazone reduces monocyte adhesion to vascular endothelium under flow by modulating RhoA GTPase and focal adhesion kinase.

  FEBS letters 20031023

• [Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].

  MMW Fortschritte der Medizin 20031009

• Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20031005

• Thiazolidinediones and blood lipids in type 2 diabetes.

  Arteriosclerosis, thrombosis, and vascular biology 20031001

• Rapid amelioration of muscle sympathetic nerve activity by pioglitazone in an obese Type 2 diabetic patient.

  Diabetic medicine : a journal of the British Diabetic Association 20031001

• Changes in glycated haemoglobin levels in diabetic rats measured with an automatic affinity HPLC.

  Clinical and experimental pharmacology & physiology 20031001

• The 'glitazones': rosiglitazone and pioglitazone.

  Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 20031001

• [Pioglitazone, a peroxisome proliferators-activated receptor gamma ligand, inhibits dimethylhydrazine (DMH) induced aberrant crypt foci in rats].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20031001

• Treating type 2 diabetes in renal insufficiency: the role of pioglitazone.

  International journal of clinical pharmacology and therapeutics 20031001

• [Fatty liver. Not only ultrasound to be relied on!].

  MMW Fortschritte der Medizin 20030925

• A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice.

  Biochemical and biophysical research communications 20030919

• Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20030915

• Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.

  Cancer research 20030915

• [Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].

  MMW Fortschritte der Medizin 20030911

• Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone.

  The Journal of pharmacology and experimental therapeutics 20030901

• Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.

  Diabetes care 20030901

• Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

  Diabetes care 20030901

• Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.

  Diabetes 20030901

• Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells.

  Thorax 20030901

• Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis.

  Cardiovascular research 20030901

• Pioglitazone-induced myofibroblast cell death: implications for cutaneous scarring.

  The British journal of dermatology 20030901

• Sex differences in the pharmacokinetics of pioglitazone in rats.

  Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20030901

• Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20030901

• Glitazones and heart failure: critical appraisal for the clinician.

  Circulation 20030826

• Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030820

• Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.

  American journal of physiology. Endocrinology and metabolism 20030801

• Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.

  Human reproduction (Oxford, England) 20030801

• Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.

  American heart journal 20030801

• Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.

  The Journal of clinical endocrinology and metabolism 20030801

• Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones.

  Atherosclerosis 20030801

• PPAR-gamma overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells.

  Biochemical and biophysical research communications 20030711

• Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat.

  European journal of pharmacology 20030711

• [Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].

  Nihon rinsho. Japanese journal of clinical medicine 20030701

• Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.

  Pharmacotherapy 20030701

• [Timely intervention with insulin sensitizer. Controlling cardiovascular risks].

  MMW Fortschritte der Medizin 20030605

• Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.

  American journal of physiology. Endocrinology and metabolism 20030601

• Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.

  Stroke 20030601

• Spectroscopic studies of some antidiabetic drugs.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20030601

• Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

  Diabetes 20030601

• Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

  Human reproduction (Oxford, England) 20030601

• Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation.

  Circulation 20030527

• Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells.

  The Journal of biological chemistry 20030523

• Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma.

  Biochemical and biophysical research communications 20030523

• Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.

  American journal of physiology. Endocrinology and metabolism 20030501

• Identification of novel metabolites of pioglitazone in rat and dog.

  Xenobiotica; the fate of foreign compounds in biological systems 20030501

• Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.

  Diabetic medicine : a journal of the British Diabetic Association 20030501

• PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro.

  Breast cancer research and treatment 20030501

• Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.

  Postgraduate medicine 20030501

• Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat.

  Scandinavian journal of gastroenterology 20030501

• Hepatotoxicity of the thiazolidinediones.

  Clinics in liver disease 20030501

• Vascular smooth muscle cell activation by C-reactive protein.

  Cardiovascular research 20030401

• Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20030401

• The pharmacokinetics of pioglitazone in patients with impaired renal function.

  British journal of clinical pharmacology 20030401

• Protective effect of pioglitazone against multiple low-dose streptozotocin-induced diabetes in rats.

  Methods and findings in experimental and clinical pharmacology 20030401

• Pioglitazone increases serum magnesium levels in glucose-intolerant subjects. A randomized, controlled trial.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20030401

• A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

  Clinical therapeutics 20030401

• Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.

  AIDS (London, England) 20030328

• [What is to be made of the therapy of borreliosis with cholestyramine and pioglitazone?].

  Deutsche medizinische Wochenschrift (1946) 20030307

• Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.

  Diabetes care 20030301

• Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030301

• [A case of drug induced liver injury related pioglitazone].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20030301

• Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)gamma activators.

  Clinical and experimental nephrology 20030301

• [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].

  MMW Fortschritte der Medizin 20030227

• Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes.

  The Journal of biological chemistry 20030221

• Initial management of glycemia in type 2 diabetes.

  The New England journal of medicine 20030220

• [Hypoglycemia associated with the production of insulin-like growth factor (IGF)-II by a hemangiopericytoma].

  Deutsche medizinische Wochenschrift (1946) 20030207

• Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.

  The Journal of endocrinology 20030201

• Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.

  Gastroenterology 20030201

• Did this drug cause my patient's hepatitis?

  Annals of internal medicine 20030121

• Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro.

  Journal of neuroscience research 20030115

• Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.

  Biochemical pharmacology 20030115

• Regulation of PPAR gamma transcriptional activity in 3T3-L1 adipocytes.

  Biochemical and biophysical research communications 20030110

• Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes.

  Diabetes care 20030101

• Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?

  The Journal of clinical endocrinology and metabolism 20030101

• Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile.

  Diabetes, obesity & metabolism 20030101

• [Thiazolidinediones: effect of the pioglitazone on hyperglycemia, dyslipidemia and cardiovascular risk].

  Revista clinica espanola 20030101

• Diabetes medicine update. Old dogs, new tricks.

  Diabetes self-management 20030101

• Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20030101

• Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen.

  Journal of diabetes and its complications 20030101

• Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

  Drugs 20030101

• Cardioprotection with pioglitazone is abolished by nitric oxide synthase inhibitor in ischemic rabbit hearts--comparison of the effects of pioglitazone and metformin.

  Diabetes/metabolism research and reviews 20030101

• Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.

  The Cochrane database of systematic reviews 20030101

• Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.

  Clinical therapeutics 20030101

• Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.

  Clinical therapeutics 20030101

• Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.

  Clinical therapeutics 20030101

• Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus.

  Current medical research and opinion 20030101

• Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.

  Diabetes/metabolism research and reviews 20030101

• Clinical effect of combination therapy of pioglitazone and an alpha-glucosidase inhibitor.

  Current medical research and opinion 20030101

• [Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20030101

• Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone.

  The Journal of biological chemistry 20021213

• [Insulin sensitizer improves lipid profile. Infarct prevention for type 2 diabetic patients?].

  MMW Fortschritte der Medizin 20021212

• Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction.

  Circulation 20021210

• Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.

  Endocrinology 20021201

• Pioglitazone: effect on CYP3A4 activity.

  Journal of clinical pharmacology 20021201

• Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

  The Journal of clinical endocrinology and metabolism 20021201

• Repaglinide in combination therapy.

  Diabetes, nutrition & metabolism 20021201

• Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone.

  Thrombosis research 20021125

• Severe but reversible cholestatic liver injury after pioglitazone therapy.

  Annals of internal medicine 20021119

• Antiinflammatory and antiarteriosclerotic effects of pioglitazone.

  Hypertension (Dallas, Tex. : 1979) 20021101

• [Discovery and development of a new insulin sensitizing agent, pioglitazone].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20021101

• [Meta-analysis shows: insulin sensitizer is safe for the liver].

  MMW Fortschritte der Medizin 20021003

• [Syndrome X].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20021001

• Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system.

  Life sciences 20020913

• Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists.

  Urology 20020901

• [Adverse effects of oral hypoglycemic agents].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Insulin sensitizer drugs--review].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Glitazone--a new drug for type 2 diabetes].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Pioglitazone].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Perspective for development of insulin sensitizers].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.

  Inflammatory bowel diseases 20020901

• Improvement of aortic wall distensibility and reduction of oxidative stress by pioglitazone in pre-diabetic stage of Otsuka Long-Evans Tokushima fatty rats.

  Cardiovascular drugs and therapy 20020901

• Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.

  Journal of neurochemistry 20020801

• Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats.

  Hypertension (Dallas, Tex. : 1979) 20020801

• Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.

  Clinical science (London, England : 1979) 20020801

• Determination of pioglitazone hydrochloride in bulk and pharmaceutical formulations by HPLC and MEKC methods.

  Journal of pharmaceutical and biomedical analysis 20020720

• Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant.

  Human molecular genetics 20020715

• Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20020701

• Oral hypoglycaemics. When not to use what.

  Australian family physician 20020701

• PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages.

  FEBS letters 20020605

• Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

  The Journal of clinical endocrinology and metabolism 20020601

• Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

  Gastroenterology 20020601

• Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance.

  Annals of the New York Academy of Sciences 20020601

• Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.

  Annals of the New York Academy of Sciences 20020601

• Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.

  Annals of neurology 20020601

• [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].

  Zhonghua nei ke za zhi 20020601

• Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.

  Endocrine journal 20020601

• The glitazones: a new treatment for type 2 diabetes mellitus.

  Intensive & critical care nursing 20020601

• [Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates 'cell ignorance'].

  MMW Fortschritte der Medizin 20020523

• [Early effect of therapy with pioglitazone. Vascular damage significantly reduced].

  MMW Fortschritte der Medizin 20020523

• Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.

  Circulation 20020514

• [Glinides and glitazones in diabetes treatment. Are they really effective?].

  MMW Fortschritte der Medizin 20020502

• [Vascular damage decides prognosis of type 2 diabetic patients. Lowering blood glucose is not enough].

  MMW Fortschritte der Medizin 20020502

• Thiazolidinediones in the treatment of type 2 diabetes.

  Expert opinion on pharmacotherapy 20020501

• Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.

  International journal of clinical practice 20020501

• Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma.

  British journal of cancer 20020422

• Thiazolidinediones and type 2 diabetes: new drugs for an old disease.

  The Medical journal of Australia 20020415

• PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.

  Circulation research 20020405

• A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.

  Diabetes care 20020401

• Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.

  Diabetic medicine : a journal of the British Diabetic Association 20020401

• Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats.

  Clinical and experimental pharmacology & physiology 20020401

• Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities.

  Journal of medicinal chemistry 20020328

• Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.

  Annals of internal medicine 20020319

• 'Did this drug cause my patient's hepatitis?' and related questions.

  Annals of internal medicine 20020319

• Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.

  Annals of internal medicine 20020319

• Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.

  Circulation 20020312

• Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.

  Diabetes care 20020301

• Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

  Metabolism: clinical and experimental 20020301

• A peroxisome proliferator-activated receptor gamma agonist influenced daily profile of energy expenditure in genetically obese diabetic rats.

  Japanese journal of pharmacology 20020301

• Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

  Clinical therapeutics 20020301

• [Type 2 diabetes. How can the infarction risk be reduced?].

  MMW Fortschritte der Medizin 20020227

• Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

  Biochemical and biophysical research communications 20020215

• Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.

  Journal of medicinal chemistry 20020214

• Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes during in vitro adipogenesis.

  Toxicological sciences : an official journal of the Society of Toxicology 20020201

• Improvement of asthma after administration of pioglitazone.

  Diabetes care 20020201

• Angioneurotic edema as a side effect of pioglitazone.

  Diabetes care 20020201

• Pioglitazone-associated fulminant hepatic failure.

  The American journal of gastroenterology 20020201

• [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].

  MMW Fortschritte der Medizin 20020124

• Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020122

• Are all glitazones the same?

  Diabetes/metabolism research and reviews 20020101

• Differentiating members of the thiazolidinedione class: a focus on efficacy.

  Diabetes/metabolism research and reviews 20020101

• Differentiating members of the thiazolidinedione class: a focus on safety.

  Diabetes/metabolism research and reviews 20020101

• New solutions for type 2 diabetes mellitus: the role of pioglitazone.

  PharmacoEconomics 20020101

• The role of models within economic analysis: focus on type 2 diabetes mellitus.

  PharmacoEconomics 20020101

• Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada.

  PharmacoEconomics 20020101

• Applications of economic models in healthcare: the introduction of pioglitazone in Sweden.

  PharmacoEconomics 20020101

• [Against insulin resistance. Insulin sensitizers].

  Pharmazie in unserer Zeit 20020101

• Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.

  Diabetes technology & therapeutics 20020101

• Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes?

  Diabetes technology & therapeutics 20020101

• Glitazones: clinical effects and molecular mechanisms.

  Annals of medicine 20020101

• Preventing the progressive nature of type 2 diabetes.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20020101

• Cardiovascular risk reduction with pioglitazone.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20020101

• Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.

  Current medical research and opinion 20020101

• Pioglitazone: cardiovascular effects in prediabetic patients.

  Cardiovascular drug reviews 20020101

• Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade.

  Redox report : communications in free radical research 20020101

• Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats.

  Redox report : communications in free radical research 20020101

• A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats.

  Redox report : communications in free radical research 20020101

• Effects of the thiazolidinediones on cardiovascular risk factors.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.

  Treatments in endocrinology 20020101

• 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells.

  The Journal of biological chemistry 20011228

• Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.

  Life sciences 20011214

• [Life expectancy decreased by 1/3rd. Who to sink the vascular risk of type 2 diabetic patients?].

  MMW Fortschritte der Medizin 20011206

• Nonhypoglycemic effects of thiazolidinediones.

  Annals of internal medicine 20011204

• Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.

  Journal of cardiovascular pharmacology 20011201

• PPARgamma and atherosclerosis: effects on cell growth and movement.

  Arteriosclerosis, thrombosis, and vascular biology 20011201

• [A trend of insulin sensitizer which is under development].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• [Pharmacological effects of a thiazolidinedione derivative, pioglitazone].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• [Evaluation of a thiazolidinedione compound as a new antidiabetic drug].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• [Evaluation of thiazolidinedione derivative drugs for safety].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• [Clinical usefulness of combination treatment with thiazolidinedione and insulin].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.

  Clinical therapeutics 20011101

• Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.

  Renal failure 20011101

• Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20011001

• Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria.

  Metabolism: clinical and experimental 20011001

• Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists.

  Biochemical and biophysical research communications 20010928

• [Glitazones--a new therapeutic principle in diabetes].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20010920

• Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.

  Atherosclerosis 20010901

• Pioglitazone and rosiglitazone for diabetes.

  Drug and therapeutics bulletin 20010901

• Pioglitazone: mechanism of action.

  International journal of clinical practice. Supplement 20010901

• Pharmacokinetics and clinical efficacy of pioglitazone.

  International journal of clinical practice. Supplement 20010901

• Safety profile of pioglitazone.

  International journal of clinical practice. Supplement 20010901

• Pioglitazone: the future.

  International journal of clinical practice. Supplement 20010901

• [News in oral antidiabetic therapy].

  Vnitrni lekarstvi 20010901

• PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.

  Biochemical and biophysical research communications 20010824

• [Glitazone--a new class of drugs for the treatment of type 2 diabetes].

  Deutsche medizinische Wochenschrift (1946) 20010824

• Hepatocellular injury in a patient receiving pioglitazone.

  Annals of internal medicine 20010821

• [The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].

  Nederlands tijdschrift voor geneeskunde 20010811

• Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.

  Diabetes 20010801

• Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth.

  Metabolism: clinical and experimental 20010801

• Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells.

  The American journal of pathology 20010801

• The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

  Coronary artery disease 20010801

• Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia.

  Circulation 20010724

• [Thiazolidinediones--a new class of oral antidiabetic drugs].

  Orvosi hetilap 20010722

• PPARgamma agonists for intestinal ischaemia.

  Lancet (London, England) 20010707

• Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20010701

• Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

  The American journal of medicine 20010701

• A new era in type 2 diabetes mellitus treatment?

  The American journal of medicine 20010701

• Actos (pioglitazone): a new treatment for type 2 diabetes.

  Hospital medicine (London, England : 1998) 20010701

• Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.

  European journal of pharmacology 20010629

• Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes.

  European journal of pharmacology 20010622

• Lessons from the glitazones: a story of drug development.

  Lancet (London, England) 20010609

• Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats.

  Alimentary pharmacology & therapeutics 20010601

• Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase.

  The Journal of biological chemistry 20010518

• Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN.

  Current biology : CB 20010515

• Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.

  Diabetes 20010501

• The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.

  Diabetes care 20010501

• Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes.

  Diabetes care 20010501

• Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects.

  Journal of clinical pharmacology 20010501

• Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.

  Hypertension research : official journal of the Japanese Society of Hypertension 20010501

• [Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010501

• Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.

  The American journal of managed care 20010401

• Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

  Diabetes care 20010401

• Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.

  Diabetes care 20010401

• [Glitazones. Profile of a new class of substances].

  Der Internist 20010401

• [Thiazolidinediones: clinical data and perspectives].

  Diabetes & metabolism 20010401

• The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells.

  Molecular pharmacology 20010301

• Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes.

  Metabolism: clinical and experimental 20010301

• Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients?

  Diabetes care 20010201

• A comprehensive review of the antidiabetic agent rosiglitazone.

  Clinical therapeutics 20010201

• Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.

  BMJ (Clinical research ed.) 20010127

• Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.

  BMJ (Clinical research ed.) 20010127

• [30-year-old diabetic patients mostly have type 2 diabetes. 'Mature' diabetics are becoming increasingly younger].

  MMW Fortschritte der Medizin 20010125

• Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010101

• New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.

  Annual review of medicine 20010101

• Honing type 2 diabetes treatment.

  Health news (Waltham, Mass.) 20010101

• Survival activity of troglitazone in rat motoneurones.

  Journal of neurochemistry 20010101

• Insulin resistance and its treatment by thiazolidinediones.

  Recent progress in hormone research 20010101

• Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20010101

• Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents.

  European journal of medicinal chemistry 20010101

• Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1.

  Digestion 20010101

• The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.

  Health technology assessment (Winchester, England) 20010101

• Hepatotoxicity with thiazolidinediones: is it a class effect?

  Drug safety 20010101

• Actos (pioglitazone).

  TreatmentUpdate 20010101

• [Drug interactions as exemplified by thiazolidinediones (glitazones). Commentary on the publication of Ulrich Klotz and Dietmar Sailer, 'Drug interactions--their impact on safe drug therapy in the example of the new thiazolidinedione group (glitazone)'Arzneimittelforschung. 2001 Feb;51(2):112-7].

  Arzneimittel-Forschung 20010101

• Pioglitazone: a review of Japanese clinical studies.

  Current medical research and opinion 20010101

• 15-Deoxy-Delta(12,14)-prostaglandin J(2) facilitates thyroglobulin production by cultured human thyrocytes.

  American journal of physiology. Cell physiology 20001201

• Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

  Biochemical and biophysical research communications 20001130

• Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells.

  European journal of pharmacology 20001103

• (3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.

  Bioorganic & medicinal chemistry letters 19990222

• Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

  Biochemical and biophysical research communications 19990127

• Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.

  European journal of pharmacology 19990108

• PPARgamma-dependent regulation of adenylate cyclase 6 amplifies the stimulatory effect of cAMP on renin gene expression.

  Molecular endocrinology (Baltimore, Md.)